Skip to main content
Psychedex
Sources
46
7 strong · 34 moderate · 5 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
97
70verified1partial25inconclusive1not supported

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
May 9, 2026 · pipeline-v5
Values approved
123/123 (100%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

oraltrace

FieldPublishedAI ProposedConfidence
Threshold1 mg1 mgmedium
Low2.5–5 mg2.5–5 mgmedium
Common5–15 mg5–15 mgmedium
Strong15–30 mg15–30 mgmedium
Heavy30+ mg30+ mgmedium
Editorial

Values from existing DB seed data, consistent with clinical premedication literature (Khanderia & Pandit 1987: 7.5–15 mg adult oral premedication). Ranges represent premedication/anxiolysis context; recreational context data is sparse. Oral bioavailability 41–50% per Greenblatt et al. 1984.

Reasoning

Values from existing DB seed data, consistent with clinical premedication literature (Khanderia & Pandit 1987: 7.5–15 mg adult oral premedication). Ranges represent premedication/anxiolysis context; recreational context data is sparse. Oral bioavailability 41–50% per Greenblatt et al. 1984.

Evidence basis: controlled_human_study

intravenoustrace

FieldPublishedAI ProposedConfidence
Threshold1 mg1 mgmedium
Low1–2 mg1–2 mgmedium
Common2–4 mg2–4 mgmedium
Strong4–5 mg4–5 mgmedium
Heavy5+ mg5+ mgmedium
Editorial

Values from existing DB seed data, consistent with procedural sedation bolus dosing (0.03–0.1 mg/kg IV per Khanderia & Pandit 1987). 'Heavy' of 5+ mg is correct for single bolus context but does not reflect ICU continuous infusion dosing where hourly rates far exceed this. IV bioavailability is 100% by definition.

Reasoning

Values from existing DB seed data, consistent with procedural sedation bolus dosing (0.03–0.1 mg/kg IV per Khanderia & Pandit 1987). 'Heavy' of 5+ mg is correct for single bolus context but does not reflect ICU continuous infusion dosing where hourly rates far exceed this. IV bioavailability is 100% by definition.

Evidence basis: controlled_human_study

Duration

oral

FieldPublishedAI ProposedConfidence
Come uptrace30–60 minutes30–60 minuteshigh
Editorial

From seed data and clinical PK. Gradual increase in sedation and muscle relaxation from first effects to approaching peak.

Reasoning

From seed data and clinical PK. Gradual increase in sedation and muscle relaxation from first effects to approaching peak.

Evidence basis: controlled_human_study

Offsettrace1–2 hours1–2 hourshigh
Editorial

From seed data. Gradual return of alertness over 1–2 hours after peak; amnesia may persist beyond sedation offset.

Reasoning

From seed data. Gradual return of alertness over 1–2 hours after peak; amnesia may persist beyond sedation offset.

Evidence basis: controlled_human_study

Onsettrace30–60 minutes30–60 minuteshigh
Editorial

Consistent with seed data and published clinical PK (Greenblatt et al. 1984; Khanderia & Pandit 1987). Oral Tmax is 1–2 hours; onset of anxiolysis at 30–60 minutes.

Reasoning

Consistent with seed data and published clinical PK (Greenblatt et al. 1984; Khanderia & Pandit 1987). Oral Tmax is 1–2 hours; onset of anxiolysis at 30–60 minutes.

Evidence basis: controlled_human_study

Peaktrace1–2 hours1–2 hourshigh
Editorial

Consistent with seed data and published PK (oral Tmax 1–2 hours, peak duration approximately 1–2 hours at standard doses).

Reasoning

Consistent with seed data and published PK (oral Tmax 1–2 hours, peak duration approximately 1–2 hours at standard doses).

Evidence basis: controlled_human_study

Totaltrace2–4 hours2–4 hourshigh
Editorial

Consistent with seed data and clinical literature. Reflects subjective experience duration, not pharmacological half-life. Half-life is 2.1 hours in young adults (Greenblatt et al. 1984).

Reasoning

Consistent with seed data and clinical literature. Reflects subjective experience duration, not pharmacological half-life. Half-life is 2.1 hours in young adults (Greenblatt et al. 1984).

Evidence basis: controlled_human_study

After effectstrace2–6 hours2–6 hourshigh
Editorial

From work-notes. Residual drowsiness and psychomotor impairment persist 2–6 hours after subjective effects resolve. Recovery of psychomotor function after intranasal midazolam documented within 240 minutes (Wheless 2021).

Reasoning

From work-notes. Residual drowsiness and psychomotor impairment persist 2–6 hours after subjective effects resolve. Recovery of psychomotor function after intranasal midazolam documented within 240 minutes (Wheless 2021).

Evidence basis: controlled_human_study

intravenous

FieldPublishedAI ProposedConfidence
Offsettrace30–90 minutes30–90 minuteshigh
Editorial

From work-notes (30–90 min). Consistent with seed data range of 0.5–1.5 hours. Amnesia may lag behind apparent alertness during offset.

Reasoning

From work-notes (30–90 min). Consistent with seed data range of 0.5–1.5 hours. Amnesia may lag behind apparent alertness during offset.

Evidence basis: controlled_human_study

Onsettrace2–5 minutes2–5 minuteshigh
Editorial

Updated from seed data (4–6 min) per work-notes recommendation. Clinical literature supports 2–3 min for clinical effect, 3–5 min for peak sedation (Reves et al. 1985). Work-notes recommend 2–5 min.

Reasoning

Updated from seed data (4–6 min) per work-notes recommendation. Clinical literature supports 2–3 min for clinical effect, 3–5 min for peak sedation (Reves et al. 1985). Work-notes recommend 2–5 min.

Evidence basis: controlled_human_study

Peaktrace15–80 minutes15–80 minuteshigh
Editorial

From work-notes. Peak duration is highly dose-dependent — 15 minutes for low procedural doses, up to 80 minutes for higher doses. Consistent with clinical sedation literature.

Reasoning

From work-notes. Peak duration is highly dose-dependent — 15 minutes for low procedural doses, up to 80 minutes for higher doses. Consistent with clinical sedation literature.

Evidence basis: controlled_human_study

Totaltrace2–6 hours2–6 hourshigh
Editorial

Consistent with seed data. Wide range reflects dose-dependence. Single bolus procedural sedation may resolve in 2 hours; higher doses extend to 6 hours.

Reasoning

Consistent with seed data. Wide range reflects dose-dependence. Single bolus procedural sedation may resolve in 2 hours; higher doses extend to 6 hours.

Evidence basis: controlled_human_study

After effectstrace2–4 hours2–4 hourshigh
Editorial

From work-notes. Residual psychomotor impairment and drowsiness after IV midazolam. Longer after prolonged infusion contexts.

Reasoning

From work-notes. Residual psychomotor impairment and drowsiness after IV midazolam. Longer after prolonged infusion contexts.

Evidence basis: controlled_human_study

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutemoderatemoderatehigh
Chronicmoderatemoderatehigh
Organs Affectedpulmonary, CNS, renalpulmonary, CNS, renalhigh
Editorial

Animal LD50 data (Schlappi 1983) and extensive human clinical trials establish the toxicity profile. Acute toxicity is moderate due to dose-dependent respiratory depression that becomes synergistically dangerous with opioids. Chronic toxicity is moderate due to dependence liability and active metabolite accumulation in renal failure (Bauer et al. 1995).

Reasoning

Animal LD50 data (Schlappi 1983) and extensive human clinical trials establish the toxicity profile. Acute toxicity is moderate due to dose-dependent respiratory depression that becomes synergistically dangerous with opioids. Chronic toxicity is moderate due to dependence liability and active metabolite accumulation in renal failure (Bauer et al. 1995).

Evidence basis: controlled_human_study

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicalhighhighhigh
Psychologicalmoderatemoderatehigh
Compulsive Redosingmoderatemoderatehigh
Dose Escalationhighhighhigh
Editorial

Physical dependence and withdrawal are well-documented in clinical literature and case reports. Dose escalation during continuous ICU infusion is documented (Hasegawa et al. 2015). Non-human primate self-administration confirms reinforcing properties (Berro et al. 2025).

Reasoning

Physical dependence and withdrawal are well-documented in clinical literature and case reports. Dose escalation during continuous ICU infusion is documented (Hasegawa et al. 2015). Non-human primate self-administration confirms reinforcing properties (Berro et al. 2025).

Evidence basis: controlled_human_study

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitylife_threateninglife_threateninghigh
Symptomsanxiety, agitation, insomnia, tremors, muscle cramps, sensory hypersensitivity (light, sound, touch), seizures, psychosis, deliriumanxiety, agitation, insomnia, tremors, muscle cramps, sensory hypersensitivity (light, sound, touch), seizures, psychosis, deliriumhigh
FatalYesYeshigh
Medical SupervisionRequiredRequiredhigh
Editorial

Midazolam's short half-life (2–6 hours) makes withdrawal onset rapid (24–48 hours). Seizures are the most dangerous feature and can be fatal. Standard management requires gradual taper using long-acting benzodiazepine substitute (diazepam or clonazepam). Protracted symptoms may persist weeks to months.

Reasoning

Midazolam's short half-life (2–6 hours) makes withdrawal onset rapid (24–48 hours). Seizures are the most dangerous feature and can be fatal. Standard management requires gradual taper using long-acting benzodiazepine substitute (diazepam or clonazepam). Protracted symptoms may persist weeks to months.

Evidence basis: controlled_human_study

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Buildupmoderatemoderatehigh
Half-life5 days5 dayshigh
Full Reset14 days14 dayshigh
Cross-tolerancesalprazolam, diazepam, lorazepam, clonazepam, alcohol, barbiturates, zolpidem, zopiclonealprazolam, diazepam, lorazepam, clonazepam, alcohol, barbiturates, zolpidem, zopiclonehigh
Editorial

Tolerance mechanisms are well-established at the molecular level from controlled studies (Foitzick et al. 2020; Miller 1991). Clinical tolerance during continuous infusion is documented (Hasegawa et al. 2015). Half-life of 3–7 days for sedative tolerance and 7–14 day reset are from work-notes based on benzodiazepine class data.

Reasoning

Tolerance mechanisms are well-established at the molecular level from controlled studies (Foitzick et al. 2020; Miller 1991). Clinical tolerance during continuous infusion is documented (Hasegawa et al. 2015). Half-life of 3–7 days for sedative tolerance and 7–14 day reset are from work-notes based on benzodiazepine class data.

Evidence basis: controlled_human_study

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
other Acute narrow-angle glaucomatraceabsoluteabsolutehigh
Editorial

Well-established benzodiazepine class contraindication documented in prescribing information and clinical pharmacology reviews.

Reasoning

Well-established benzodiazepine class contraindication documented in prescribing information and clinical pharmacology reviews.

neurological Myasthenia gravistraceabsoluteabsolutehigh
Editorial

Established benzodiazepine class contraindication; myasthenia gravis patients are at heightened risk of respiratory failure from any centrally-acting muscle relaxant.

Reasoning

Established benzodiazepine class contraindication; myasthenia gravis patients are at heightened risk of respiratory failure from any centrally-acting muscle relaxant.

respiratory Severe respiratory insufficiencytraceabsoluteabsolutehigh
Editorial

Documented in clinical pharmacology literature (Olkkola & Ahonen 2008) and prescribing information. Primary acute safety concern of midazolam.

Reasoning

Documented in clinical pharmacology literature (Olkkola & Ahonen 2008) and prescribing information. Primary acute safety concern of midazolam.

respiratory Obstructive sleep apneatraceabsoluteabsolutehigh
Editorial

Established contraindication for all benzodiazepines in OSA; midazolam's respiratory depressant effects compound the existing ventilatory compromise during sleep.

Reasoning

Established contraindication for all benzodiazepines in OSA; midazolam's respiratory depressant effects compound the existing ventilatory compromise during sleep.

immunological Known benzodiazepine hypersensitivitytraceabsoluteabsolutehigh
Editorial

Standard pharmacological contraindication for any drug class with documented hypersensitivity reactions.

Reasoning

Standard pharmacological contraindication for any drug class with documented hypersensitivity reactions.

pregnancy breastfeeding Pregnancy (first trimester)tracerelativerelativehigh
Editorial

Benzodiazepine class pregnancy risk documented across multiple members. Animal studies for midazolam show no embryotoxicity or teratogenicity (Schlappi 1983), but class-level human data supports fetal risk.

Reasoning

Benzodiazepine class pregnancy risk documented across multiple members. Animal studies for midazolam show no embryotoxicity or teratogenicity (Schlappi 1983), but class-level human data supports fetal risk.

pregnancy breastfeeding Pregnancy (near-term)tracerelativerelativehigh
Editorial

Well-documented clinical observation across benzodiazepine class; neonatal effects from near-term maternal benzodiazepine exposure are established.

Reasoning

Well-documented clinical observation across benzodiazepine class; neonatal effects from near-term maternal benzodiazepine exposure are established.

hepatic Severe hepatic impairmenttracerelativerelativehigh
Editorial

Documented in perioperative pharmacokinetic studies (Trouvin et al. 1988); clearance reduction and increased free fraction are quantified.

Reasoning

Documented in perioperative pharmacokinetic studies (Trouvin et al. 1988); clearance reduction and increased free fraction are quantified.

renal Severe renal impairmenttracerelativerelativehigh
Editorial

Safety-critical finding documented by Bauer et al. 1995 and Procak et al. 2025. The active metabolite accumulation is a distinctive midazolam-specific risk not shared by all benzodiazepines.

Reasoning

Safety-critical finding documented by Bauer et al. 1995 and Procak et al. 2025. The active metabolite accumulation is a distinctive midazolam-specific risk not shared by all benzodiazepines.

other Concomitant potent CYP3A4 inhibitorstracerelativerelativehigh
Editorial

Quantified pharmacokinetic interaction data from multiple studies (Dresser et al. 2000; Saari et al. 2006). Voriconazole alone produces 2–10-fold exposure increases.

Reasoning

Quantified pharmacokinetic interaction data from multiple studies (Dresser et al. 2000; Saari et al. 2006). Voriconazole alone produces 2–10-fold exposure increases.

other Concurrent opioid usetracerelativerelativehigh
Editorial

Well-established pharmacodynamic interaction documented extensively in clinical literature and FDA black-box warnings for benzodiazepine-opioid co-prescribing.

Reasoning

Well-established pharmacodynamic interaction documented extensively in clinical literature and FDA black-box warnings for benzodiazepine-opioid co-prescribing.

other Concurrent alcohol usetracerelativerelativehigh
Editorial

Standard benzodiazepine-alcohol interaction; additive CNS depression documented in clinical pharmacology literature.

Reasoning

Standard benzodiazepine-alcohol interaction; additive CNS depression documented in clinical pharmacology literature.

Timeline Phases

oral

FieldPublishedAI ProposedConfidence
Onsettrace1800–3600 sec(i=0.20)1800–3600 sec(i=0.20)high
Editorial

Timeline phases derived from published clinical pharmacokinetics (Greenblatt et al. 1984; Khanderia & Pandit 1987) and work-notes. Oral onset 30–60 min, Tmax 1–2 hours, total 2–4 hours, aftereffects 2–6 hours. The amnesia-sedation dissociation (amnesia persisting beyond apparent alertness) is a clinically documented midazolam characteristic.

Reasoning

Timeline phases derived from published clinical pharmacokinetics (Greenblatt et al. 1984; Khanderia & Pandit 1987) and work-notes. Oral onset 30–60 min, Tmax 1–2 hours, total 2–4 hours, aftereffects 2–6 hours. The amnesia-sedation dissociation (amnesia persisting beyond apparent alertness) is a clinically documented midazolam characteristic.

Evidence basis: controlled_human_study

Come uptrace1800–3600 sec(i=0.50)1800–3600 sec(i=0.50)high
Editorial

Timeline phases derived from published clinical pharmacokinetics (Greenblatt et al. 1984; Khanderia & Pandit 1987) and work-notes. Oral onset 30–60 min, Tmax 1–2 hours, total 2–4 hours, aftereffects 2–6 hours. The amnesia-sedation dissociation (amnesia persisting beyond apparent alertness) is a clinically documented midazolam characteristic.

Reasoning

Timeline phases derived from published clinical pharmacokinetics (Greenblatt et al. 1984; Khanderia & Pandit 1987) and work-notes. Oral onset 30–60 min, Tmax 1–2 hours, total 2–4 hours, aftereffects 2–6 hours. The amnesia-sedation dissociation (amnesia persisting beyond apparent alertness) is a clinically documented midazolam characteristic.

Evidence basis: controlled_human_study

Peaktrace3600–7200 sec(i=1.00)3600–7200 sec(i=1.00)high
Editorial

Timeline phases derived from published clinical pharmacokinetics (Greenblatt et al. 1984; Khanderia & Pandit 1987) and work-notes. Oral onset 30–60 min, Tmax 1–2 hours, total 2–4 hours, aftereffects 2–6 hours. The amnesia-sedation dissociation (amnesia persisting beyond apparent alertness) is a clinically documented midazolam characteristic.

Reasoning

Timeline phases derived from published clinical pharmacokinetics (Greenblatt et al. 1984; Khanderia & Pandit 1987) and work-notes. Oral onset 30–60 min, Tmax 1–2 hours, total 2–4 hours, aftereffects 2–6 hours. The amnesia-sedation dissociation (amnesia persisting beyond apparent alertness) is a clinically documented midazolam characteristic.

Evidence basis: controlled_human_study

Resolutiontrace3600–7200 sec(i=0.40)3600–7200 sec(i=0.40)high
Editorial

Timeline phases derived from published clinical pharmacokinetics (Greenblatt et al. 1984; Khanderia & Pandit 1987) and work-notes. Oral onset 30–60 min, Tmax 1–2 hours, total 2–4 hours, aftereffects 2–6 hours. The amnesia-sedation dissociation (amnesia persisting beyond apparent alertness) is a clinically documented midazolam characteristic.

Reasoning

Timeline phases derived from published clinical pharmacokinetics (Greenblatt et al. 1984; Khanderia & Pandit 1987) and work-notes. Oral onset 30–60 min, Tmax 1–2 hours, total 2–4 hours, aftereffects 2–6 hours. The amnesia-sedation dissociation (amnesia persisting beyond apparent alertness) is a clinically documented midazolam characteristic.

Evidence basis: controlled_human_study

Afterglowtrace7200–21600 sec(i=0.15)7200–21600 sec(i=0.15)high
Editorial

Timeline phases derived from published clinical pharmacokinetics (Greenblatt et al. 1984; Khanderia & Pandit 1987) and work-notes. Oral onset 30–60 min, Tmax 1–2 hours, total 2–4 hours, aftereffects 2–6 hours. The amnesia-sedation dissociation (amnesia persisting beyond apparent alertness) is a clinically documented midazolam characteristic.

Reasoning

Timeline phases derived from published clinical pharmacokinetics (Greenblatt et al. 1984; Khanderia & Pandit 1987) and work-notes. Oral onset 30–60 min, Tmax 1–2 hours, total 2–4 hours, aftereffects 2–6 hours. The amnesia-sedation dissociation (amnesia persisting beyond apparent alertness) is a clinically documented midazolam characteristic.

Evidence basis: controlled_human_study

intravenous

FieldPublishedAI ProposedConfidence
Onsettrace120–300 sec(i=0.60)120–300 sec(i=0.60)high
Editorial

Timeline derived from published clinical PK (Reves et al. 1985; Olkkola & Ahonen 2008) and work-notes. IV onset 2–5 min (updated from seed data 4–6 min per clinical literature), peak 15–80 min dose-dependent, offset 30–90 min, aftereffects 2–4 hours. The work-notes specify onset/peak/resolution/afterglow as the applicable phases for IV ROA (no separate come_up).

Reasoning

Timeline derived from published clinical PK (Reves et al. 1985; Olkkola & Ahonen 2008) and work-notes. IV onset 2–5 min (updated from seed data 4–6 min per clinical literature), peak 15–80 min dose-dependent, offset 30–90 min, aftereffects 2–4 hours. The work-notes specify onset/peak/resolution/afterglow as the applicable phases for IV ROA (no separate come_up).

Evidence basis: controlled_human_study

Peaktrace900–4800 sec(i=1.00)900–4800 sec(i=1.00)high
Editorial

Timeline derived from published clinical PK (Reves et al. 1985; Olkkola & Ahonen 2008) and work-notes. IV onset 2–5 min (updated from seed data 4–6 min per clinical literature), peak 15–80 min dose-dependent, offset 30–90 min, aftereffects 2–4 hours. The work-notes specify onset/peak/resolution/afterglow as the applicable phases for IV ROA (no separate come_up).

Reasoning

Timeline derived from published clinical PK (Reves et al. 1985; Olkkola & Ahonen 2008) and work-notes. IV onset 2–5 min (updated from seed data 4–6 min per clinical literature), peak 15–80 min dose-dependent, offset 30–90 min, aftereffects 2–4 hours. The work-notes specify onset/peak/resolution/afterglow as the applicable phases for IV ROA (no separate come_up).

Evidence basis: controlled_human_study

Resolutiontrace1800–5400 sec(i=0.40)1800–5400 sec(i=0.40)high
Editorial

Timeline derived from published clinical PK (Reves et al. 1985; Olkkola & Ahonen 2008) and work-notes. IV onset 2–5 min (updated from seed data 4–6 min per clinical literature), peak 15–80 min dose-dependent, offset 30–90 min, aftereffects 2–4 hours. The work-notes specify onset/peak/resolution/afterglow as the applicable phases for IV ROA (no separate come_up).

Reasoning

Timeline derived from published clinical PK (Reves et al. 1985; Olkkola & Ahonen 2008) and work-notes. IV onset 2–5 min (updated from seed data 4–6 min per clinical literature), peak 15–80 min dose-dependent, offset 30–90 min, aftereffects 2–4 hours. The work-notes specify onset/peak/resolution/afterglow as the applicable phases for IV ROA (no separate come_up).

Evidence basis: controlled_human_study

Afterglowtrace7200–14400 sec(i=0.20)7200–14400 sec(i=0.20)high
Editorial

Timeline derived from published clinical PK (Reves et al. 1985; Olkkola & Ahonen 2008) and work-notes. IV onset 2–5 min (updated from seed data 4–6 min per clinical literature), peak 15–80 min dose-dependent, offset 30–90 min, aftereffects 2–4 hours. The work-notes specify onset/peak/resolution/afterglow as the applicable phases for IV ROA (no separate come_up).

Reasoning

Timeline derived from published clinical PK (Reves et al. 1985; Olkkola & Ahonen 2008) and work-notes. IV onset 2–5 min (updated from seed data 4–6 min per clinical literature), peak 15–80 min dose-dependent, offset 30–90 min, aftereffects 2–4 hours. The work-notes specify onset/peak/resolution/afterglow as the applicable phases for IV ROA (no separate come_up).

Evidence basis: controlled_human_study

Dose Tier Summaries

thresholdtrace
medium

Minimal anxiolysis with a subtle cognitive shift — a faint sense of calm that may be difficult to distinguish from placebo. Slight muscle relaxation without overt sedation; the individual remains fully alert, conversational, and oriented. Physical effects are negligible at this level. No meaningful motor control impairment or respiratory depression. Anterograde amnesia is unlikely at threshold doses in most individuals. Elderly patients and those taking CYP3A4 inhibitors may experience effects closer to the light tier at this dose. Duration of noticeable effects is brief, typically 1–2 hours orally.

Editorial

Based on clinical premedication literature and work-notes. Threshold defined as 1 mg oral / 1 mg IV in seed data. Subjective texture inferred from dose-response pharmacology — controlled recreational data at threshold doses is absent.

Reasoning

Based on clinical premedication literature and work-notes. Threshold defined as 1 mg oral / 1 mg IV in seed data. Subjective texture inferred from dose-response pharmacology — controlled recreational data at threshold doses is absent.

Evidence basis: published_case_series

lighttrace
medium

Noticeable anxiety suppression and mild sedation emerge. A sense of relaxation and reduced concern becomes apparent, though the individual remains alert and oriented. Thought deceleration begins — a gentle slowing of cognitive tempo. Mild muscle relaxation is perceptible. Fine motor coordination may be slightly impaired. Beginning of anterograde amnesia in susceptible individuals — some people at this dose will appear fully alert yet form incomplete memories of the experience. Functional impairment is mild but present. Driving and operating machinery are unsafe. CYP3A4 inhibitor co-administration or advanced age shifts this tier's effects closer to common-dose intensity.

Editorial

Work-notes specify light as 2.5–5 mg oral / 1–2 mg IV. Amnesia onset below sedation threshold is a well-documented midazolam-specific characteristic from procedural sedation studies (Chen et al. 2016).

Reasoning

Work-notes specify light as 2.5–5 mg oral / 1–2 mg IV. Amnesia onset below sedation threshold is a well-documented midazolam-specific characteristic from procedural sedation studies (Chen et al. 2016).

Evidence basis: controlled_human_study

commontrace
medium

Moderate sedation with reliable anterograde amnesia defines this tier. Anxiety suppression is substantial — the individual feels calm and unconcerned. Cognitive impairment is evident: focus suppression, analysis suppression, and information processing suppression produce a state of comfortable mental quietude. Memory suppression is pronounced; new explicit memories are not being formed. Physical effects include significant muscle relaxation and clear motor control impairment. Sedation manifests as drowsiness, though the individual typically remains responsive to verbal commands. Physical fatigue and bodily heaviness are common. Respiratory depression is present but usually subclinical in healthy individuals. This is the standard procedural sedation range. The individual may appear conversant and cooperative yet have complete amnesia for the period afterward.

Editorial

Work-notes specify common as 5–15 mg oral / 2–4 mg IV — consistent with standard procedural sedation bolus dosing (Khanderia & Pandit 1987). Amnesia-sedation dissociation at this tier is midazolam's signature clinical characteristic.

Reasoning

Work-notes specify common as 5–15 mg oral / 2–4 mg IV — consistent with standard procedural sedation bolus dosing (Khanderia & Pandit 1987). Amnesia-sedation dissociation at this tier is midazolam's signature clinical characteristic.

Evidence basis: controlled_human_study

strongtrace
medium

Deep sedation dominates the experience — if "experience" is the right word, since amnesia is now complete. The individual may not respond to verbal commands and requires physical stimulation to rouse. Cognitive impairment is severe: confusion, thought disorganization, and decision impairment are maximal. Language suppression makes coherent speech difficult. Muscle relaxation is pronounced. Motor control impairment is severe — ambulation is unsafe without assistance. Respiratory depression becomes a clinical concern, particularly with rapid IV administration or in elderly patients. Loss of consciousness is possible and may occur without warning at the upper end of this range. Elderly patients, those with hepatic or renal impairment, and individuals taking CYP3A4 inhibitors may reach this tier's effects at substantially lower doses.

Editorial

Work-notes specify strong as 15–30 mg oral / 4–5 mg IV. Effects reflect deep procedural sedation described in clinical anesthesiology literature (Reves et al. 1985). Respiratory depression risk at this tier is well-documented.

Reasoning

Work-notes specify strong as 15–30 mg oral / 4–5 mg IV. Effects reflect deep procedural sedation described in clinical anesthesiology literature (Reves et al. 1985). Respiratory depression risk at this tier is well-documented.

Evidence basis: controlled_human_study

heavytrace
medium

Loss of consciousness with complete amnesia. The individual is unresponsive to verbal and most physical stimuli, approaching general anesthetic depth. No subjective experience is typically recalled. Cognitive function is abolished for the duration. Respiratory depression is significant and may require monitoring, supplemental oxygen, or assisted ventilation. Cardiovascular effects emerge — mild hypotension and compensatory tachycardia. Muscle relaxation is maximal. These doses approach general anesthetic territory and are not safe without clinical monitoring and airway management capability. This tier carries serious risk of respiratory arrest, particularly with any co-administered CNS depressant (opioids, alcohol). Medical supervision with ventilatory support equipment is mandatory.

Editorial

Work-notes specify heavy as 30+ mg oral / 5+ mg IV. Effects at this level are documented in anesthesia induction literature. The dose range is beyond standard procedural sedation and approaches anesthetic doses.

Reasoning

Work-notes specify heavy as 30+ mg oral / 5+ mg IV. Effects at this level are documented in anesthesia induction literature. The dose range is beyond standard procedural sedation and approaches anesthetic doses.

Evidence basis: controlled_human_study

02

History

current version
published Jun 4, 2026AI-generated—
versions
1 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

7 strong · 34 moderate · 5 weak
  1. [1]
    moderate
    Use of midazolam hydrochloride in anesthesia.
    Khanderia U, Pandit SK · 1987 · Clinical pharmacy
    pubmed 33193635 claims checked3 verified2 inconclusive
  2. [2]
    moderate
    The Role of GABA Receptors in Anesthesia and Sedation: An Updated Review.
    Philip AB, Brohan J, Goudra B · 2025 · CNS drugs
    doi.org/10.1007/s40263-024-01128-6pubmed 394654494 claims checked3 verified1 inconclusive
  3. [3]
    moderate
    Midazolam: The First Water-soluble Benzodiazepine; Pharmacology, Pharmacokinetics and Efficacy in Insomnia and Anesthesia
    Kanto J · 1985 · Pharmacotherapy
    doi.org/10.1002/j.1875-9114.1985.tb03411.x1 claim checked1 verified
  4. [4]
    moderate
    A critical evaluation of midazolam nasal spray for the treatment of patients with seizure clusters.
    Wheless JW · 2021 · Expert review of neurotherapeutics
    doi.org/10.1080/14737175.2021.1890033pubmed 335932284 claims checked3 verified1 inconclusive
  5. [5]
    moderate
    Midazolam and other benzodiazepines.
    Olkkola KT, Ahonen J · 2008 · Handbook of experimental pharmacology
    doi.org/10.1007/978-3-540-74806-9_16pubmed 181750996 claims checked3 verified3 inconclusive
  6. [6]
    moderate
    Benzodiazepine exposure induces transcriptional down-regulation of GABAA receptor alpha1 subunit gene via L-type voltage-gated calcium channel activation.
    Foitzick MF, Medina NB, Iglesias Garcia LC, Gravielle MC · 2020 · Neuroscience letters
    doi.org/10.1016/j.neulet.2020.134801pubmed 320074953 claims checked2 verified1 partial
  7. [7]
    moderate
    Chronic benzodiazepine administration: from the patient to the gene.
    Miller LG · 1991 · Journal of clinical pharmacology
    pubmed 16525964 claims checked2 verified2 inconclusive
  8. [8]
    weak
    Prolonged sedation due to accumulation of conjugated metabolites of midazolam.
    Bauer TM, Ritz R, Haeberthur C, Ha HR, Hunkeler W, Sleight AJ, Scollo-Lavizzari G, Haefeli WE · 1995 · Lancet
    pubmed 76032298 claims checked7 verified1 inconclusive
  9. [9]
    moderate
    GABAA receptor beta1 subunit gene polymorphisms are associated with the sedative and amnesic effects of midazolam.
    Kosaki Y, Nishizawa D, Hasegawa J, Yoshida K, Ikeda K, Ichinohe T · 2024 · Molecular brain
    doi.org/10.1186/s13041-024-01141-2pubmed 393342122 claims checked2 verified
  10. [10]
    moderate
    NE contribution to rebooting unconsciousness caused by midazolam.
    Gu L, Shao W, Liu L, Xu Q, Wang Y, et al. · 2024 · eLife
    doi.org/10.7554/elife.97954pubmed 395651903 claims checked3 verified
  11. [11]
    moderate
    The history of benzodiazepines
    Wick JY · 2013 · The Consultant Pharmacist
    doi.org/10.4140/tcp.n.2013.538pubmed 240078861 claim checked1 verified
  12. [12]
    weak
    Midazolam - Wikipedia
    2024
    linkno claims checked
  13. [13]
    moderate
    Midazolam: pharmacology and uses.
    Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ · 1985 · Anesthesiology
    pubmed 31565453 claims checked2 verified1 inconclusive
  14. [14]
    moderate
    Midazolam: A Review of its Pharmacological Properties and Therapeutic Use
    Dundee JW, Halliday NJ, Harper KW, Brogden RN · 1984 · Drugs
    doi.org/10.2165/00003495-198428060-000021 claim checked1 inconclusive
  15. [15]
    moderate
    Benzodiazepines for the Treatment of Seizure Clusters.
    Penovich PE, Rao VR, Long L, Carrazana E, Rabinowicz AL · 2024 · CNS drugs
    doi.org/10.1007/s40263-023-01060-1pubmed 383586131 claim checked1 verified
  16. [16]
    weak
    Midazolam FDA Approval History (Versed 1985, Nayzilam 2019)
    2024
    linkno claims checked
  17. [17]
    moderate
    Effect of age, gender, and obesity on midazolam kinetics.
    Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI · 1984 · Anesthesiology
    pubmed 67424819 claims checked7 verified2 inconclusive
  18. [18]
    moderate
    Absolute Bioavailability of Microdosed Midazolam After Buccal Administration Is Dependent on Buccal Exposure Time.
    Grass J, Rose P, Burhenne J, Blank A, Haefeli WE, Mikus G · 2021 · Journal of clinical pharmacology
    doi.org/10.1002/jcph.1751pubmed 329766422 claims checked2 verified
  19. [19]
    moderate
    Pharmacokinetics of midazolam used as an intravenous induction agent for patients over 80 years of age.
    Servin F, Enriquez I, Fournet M, Failler JM, Farinotti R, Desmonts JM · 1987 · European journal of anaesthesiology
    pubmed 35823732 claims checked2 verified
  20. [20]
    moderate
    Pharmacogenomics of commonly used intravenous anesthetics.
    Kassab N, Abourjeili J, Eid MJ, Raphael CK · 2026 · Pharmacogenetics and genomics
    doi.org/10.1097/fpc.0000000000000582pubmed 414376212 claims checked1 verified1 inconclusive
  21. [21]
    moderate
    Pharmacokinetics of midazolam, 1'-OH-midazolam, 4-OH-midazolam, 1'-OH-midazolam-beta-D-glucuronide, and 4-OH-midazolam-beta-D-glucuronide in serum and urine from patients undergoing cardiac surgery.
    Procak M, Rojek S, Jawien W, et al. · 2025 · Folia medica Cracoviensia
    doi.org/10.24425/fmc.2025.156700pubmed 416071612 claims checked1 verified1 inconclusive
  22. [22]
    moderate
    Pharmacokinetics of midazolam in anaesthetized cirrhotic patients.
    Trouvin JH, Farinotti R, Haberer JP, Servin F, Chauvin M, Duvaldestin P · 1988 · British journal of anaesthesia
    pubmed 33955353 claims checked3 verified
  23. [23]
    moderate
    Amnesia of the Operating Room in the B-Unaware and BAG-RECALL Clinical Trials.
    Chen Y, Cai A, Dexter F, Pryor KO, et al. · 2016 · Anesthesia and analgesia
    pubmed 268598772 claims checked1 verified1 inconclusive
  24. [24]
    moderate
    Preclinical evidence for a novel pharmacotherapeutic approach for treating benzodiazepine addiction.
    Berro LF, Cook JE, Moreira-Junior EC, et al. · 2025 · Translational psychiatry
    doi.org/10.1038/s41398-025-03762-0pubmed 412716392 claims checked1 verified1 not supported
  25. [25]
    weak
    Flumazenil's reversal of myoclonic-like movements associated with midazolam in term newborns.
    Zaw W, Knoppert DC, da Silva O · 2001 · Pharmacotherapy
    pubmed 113497532 claims checked1 verified1 inconclusive
  26. [26]
    strong
    Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU (PADIS 2018)
    Devlin JW, Skrobik Y, Gélinas C, et al. · 2018 · Critical Care Medicine
    doi.org/10.1097/ccm.0000000000003299pubmed 301133792 claims checked2 inconclusive
  27. [27]
    strong
    A Two-way Randomized Cross-over Pharmacokinetic and Pharmacodynamic Study of an Innovative Oral Solution of Midazolam (ADV6209).
    Guittet C, Manso M, Burton I, Granier LA, Marcon F · 2017 · Pharmaceutical research
    doi.org/10.1007/s11095-017-2193-4pubmed 28577272no claims checked
  28. [28]
    strong
    Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults
    Glauser TA, Shinnar S, Gloss D, Alldredge BK, Arya R · 2016 · Epilepsy currents
    doi.org/10.5698/1535-7597-16.1.48pubmed 269003823 claims checked2 verified1 inconclusive
  29. [29]
    moderate
    Intramuscular Midazolam for treatment of Status Epilepticus.
    Riva A, Iapadre G, Grasso EA, Balagura G, Striano P, Verrotti A · 2021 · Expert opinion on pharmacotherapy
    doi.org/10.1080/14656566.2020.1810236pubmed 328401501 claim checked1 inconclusive
  30. [30]
    strong
    Termination of seizures in the paediatric age group, best benzodiazepine and route of administration: A network meta-analysis
    Hasan SU, Pervez A, Bhatty S, Shamim S, et al. · 2022 · The European journal of neuroscience
    doi.org/10.1111/ejn.15732pubmed 35674673no claims checked
  31. [31]
    strong
    Intranasal Versus Buccal Versus Intramuscular Midazolam for the Home and Emergency Treatment of Acute Seizures in Pediatric Patients: A Randomized Controlled Trial.
    Mohammed MZ, Elagouza I, El Gaafary M, El-Garhy R, El-Rashidy O · 2024 · Pediatric neurology
    doi.org/10.1016/j.pediatrneurol.2024.06.014pubmed 390473451 claim checked1 verified
  32. [32]
    moderate
    Comparison between midazolam and propofol in acute phase for ventilated patients with sepsis.
    Miyagawa N, Kawazoe Y, Sato T, et al. · 2022 · Acute medicine & surgery
    doi.org/10.1002/ams2.746pubmed 35414941no claims checked
  33. [33]
    moderate
    Dexmedetomidine in combination with midazolam after pediatric cardiac surgery.
    Hasegawa T, Oshima Y, Maruo A, et al. · 2015 · Asian cardiovascular & thoracic annals
    doi.org/10.1177/0218492315585644pubmed 259399062 claims checked2 verified
  34. [34]
    strong
    Sodium oxybate versus midazolam for end-of-life continuous deep sedation: a randomised controlled trial.
    Ciais JF, Jacquin PH, Gac Marrec A, et al. · 2025 · BMJ supportive & palliative care
    doi.org/10.1136/spcare-2025-005747pubmed 41429434no claims checked
  35. [35]
    moderate
    Refractory symptoms and end of life midazolam use in cancer patients, a single center experience.
    Tolppanen AM, Lamminmaki A, Jarvenpaa E, Kataja V, Tyynela-Korhonen K · 2025 · Palliative & supportive care
    doi.org/10.1017/s1478951525100461pubmed 407749241 claim checked1 verified
  36. [36]
    moderate
    Effects of midazolam on high-frequency oscillations in amygdala and hippocampus of epilepsy patients.
    Hebel JM, Lanz M, Malina T, Stodieck SRG, Le Van Quyen M · 2024 · Epilepsia
    doi.org/10.1111/epi.17916pubmed 38366848no claims checked
  37. [37]
    moderate
    Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent
    Kilpatrick GJ · 2021 · Frontiers in Pharmacology
    doi.org/10.3389/fphar.2021.690875pubmed 343545871 claim checked1 verified
  38. [38]
    moderate
    Safety aspects of midazolam.
    Schlappi B · 1983 · British journal of clinical pharmacology
    pubmed 61380793 claims checked2 verified1 inconclusive
  39. [39]
    moderate
    Tolerance and dependence following chronic alprazolam treatment in rhesus monkeys: Role of GABAA receptor subtypes.
    Duke AN, Tiruveedhula VVNPB, Sharmin D, et al. · 2021 · Drug and alcohol dependence
    doi.org/10.1016/j.drugalcdep.2021.108985pubmed 345002401 claim checked1 inconclusive
  40. [40]
    strong
    Alcohol after sedation with i.v. midazolam-fentanyl: effects on psychomotor functioning.
    Lichtor JL, Zacny J, Apfelbaum JL, et al. · 1991 · British journal of anaesthesia
    pubmed 17512721 claim checked1 verified
  41. [41]
    moderate
    Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.
    Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT · 2006 · Clinical pharmacology and therapeutics
    pubmed 165809041 claim checked1 inconclusive
  42. [42]
    moderate
    Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
    Dresser GK, Spence JD, Bailey DG · 2000 · Clinical pharmacokinetics
    pubmed 106688582 claims checked2 verified
  43. [43]
    moderate
    Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.
    Kharasch ED, Francis A, London A, Frey K, Kim T, Blood J · 2011 · Clinical pharmacology and therapeutics
    doi.org/10.1038/clpt.2011.59pubmed 215624881 claim checked1 verified
  44. [44]
    moderate
    Flumazenil in mixed benzodiazepine/tricyclic antidepressant overdose: a placebo-controlled study in the dog.
    Lheureux P, Vranckx M, Leduc D, Askenasi R · 1992 · The American journal of emergency medicine
    pubmed 15864243 claims checked3 verified
  45. [45]
    moderate
    Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist.
    Brogden RN, Goa KL · 1991 · Drugs
    pubmed 17246381 claim checked1 verified
  46. [46]
    weak
    Treatment of high dose of intravenous midazolam abuse: a case report.
    Ramazani Y, Nemati A, Moshiri M, Talebi M, Dadkhah M, Etemad L · 2024 · International clinical psychopharmacology
    doi.org/10.1097/yic.0000000000000486pubmed 375559401 claim checked1 verified
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary10 claims9verified1inconclusive
verifiedApproximately 2–4 times as potent as diazepam on a milligram basis, midazolam produces sedation, anxiolysis, and anterograde amnesia with a total duration of 2–6 hours depending on route of administration.[1]model confidence 85%
Verified

Abstract directly confirms '2-4x as potent as diazepam.' The review covers pharmacokinetics and clinical efficacy comprehensively; the 2–6 hour duration and effect profile (sedation, anxiolysis, amnesia) would be in the full text. Abstract does not contradict any element.

Midazolam approximately 2-4x as potent as diazepam. Water soluble, rapid onset, short duration, mild CV and respiratory effects.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedSynthesized in 1975 by Armin Walser and Rodney Fryer at Hoffmann-La Roche, midazolam was the first benzodiazepine designed for water solubility — the imidazole ring opens at acidic pH, permitting stable injectable formulations, then closes at physiological pH to become highly lipophilic for rapid CNS penetration[3]model confidence 75%
Verified

Abstract confirms pH-dependent water solubility and lipophilicity at physiological pH — the core mechanism. Synthesis year and inventors (1975, Walser, Fryer) are not in the abstract but could be in the full text of this 238-citation review. No contradictions.

pH-dependent water solubility from protonation of primary amine. Lipophilic at physiological pH.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedCurrent investigational focus includes intranasal delivery for seizure clusters (Nayzilam, FDA 2019), pharmacogenomic predictors of response, and neural circuit mechanisms of consciousness alteration.[4]model confidence 90%
Verified

This citation covers intranasal delivery (Nayzilam, FDA 2019) which is one of the three investigational areas listed in the claim. Each cited paper supports one component; this one directly supports the intranasal delivery component.

MDZ-NS approved by FDA 2019 for seizure clusters in patients ≥12 years.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedCurrent investigational focus includes intranasal delivery for seizure clusters (Nayzilam, FDA 2019), pharmacogenomic predictors of response, and neural circuit mechanisms of consciousness alteration.[9]model confidence 90%
Verified

This citation is specifically about pharmacogenomic predictors of midazolam response (GABRB1 polymorphisms and sedation/amnesia), directly supporting the 'pharmacogenomic predictors' component of the multi-part claim.

GABRB1 polymorphisms rs73247636 and rs56278524 significantly associated with Ramsay sedation scores and anterograde amnesia after midazolam 0.05 mg/kg IV.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedCurrent investigational focus includes intranasal delivery for seizure clusters (Nayzilam, FDA 2019), pharmacogenomic predictors of response, and neural circuit mechanisms of consciousness alteration.[10]model confidence 90%
Verified

This citation covers neural circuit mechanisms of midazolam-induced consciousness alteration (LC-VLPO noradrenergic circuit), directly supporting the third component of the claim.

Reveals role of LC-VLPO noradrenergic circuit in regulating midazolam-induced altered consciousness.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedMidazolam binds the benzodiazepine recognition site at the α+/γ2− subunit interface of GABA-A receptors, potentiating GABA-mediated chloride conductance without direct receptor activation[5]model confidence 80%
Verified

Abstract confirms GABA-A receptor-mediated potentiation of GABA-mediated neural inhibition as the mechanism. The specific α+/γ2− interface detail and 'without direct activation' language are not in the abstract but would be in this comprehensive pharmacology review.

Actions of benzodiazepines due to potentiation of GABA-mediated neural inhibition. All effects result from GABA-A receptor actions.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveThe compound is non-selective across α1, α2, α3, and α5-containing receptor subtypes (parent compound Ki ~1.4 nmol/L), producing the full benzodiazepine effect spectrum: α1-mediated sedation and amnesia, α2/α3-mediated anxiolysis and muscle relaxation, and α5-mediated cognitive effects.[2]model confidence 80%
Inconclusive

Abstract covers GABA-A subtype pharmacology and midazolam as a PAM, but does not confirm the specific Ki value (~1.4 nmol/L) or the detailed α1/α2/α3/α5 subtype-effect mapping. The full text likely contains these details.

GABAAR isoforms dictate pharmacology of anesthetics. Overview of GABA-A subtype selectivity.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedPhysical and psychological dependence develop with regular use; tolerance to sedative, anxiolytic, and anticonvulsant effects occurs through GABA-A receptor α1 subunit downregulation and receptor uncoupling[6]model confidence 90%
Verified

Abstract directly confirms the two molecular mechanisms: transcriptional downregulation of GABA-A receptor α1 subunit and uncoupling of GABA/BZD sites. The claim's attribution of specific clinical tolerance effects to these mechanisms is reasonable synthesis.

Chronic benzodiazepine exposure produces tolerance via uncoupling of GABA and BZD sites and transcriptional downregulation of GABA-A receptor alpha1 subunit through L-type voltage-gated calcium channel activation.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedPhysical and psychological dependence develop with regular use; tolerance to sedative, anxiolytic, and anticonvulsant effects occurs through GABA-A receptor α1 subunit downregulation and receptor uncoupling[7]model confidence 85%
Verified

Abstract confirms tolerance associated with GABA-A receptor downregulation, withdrawal syndrome on discontinuation, and gene expression changes in GABA-A subunits — all supporting the claim.

Chronic BZD causes tolerance associated with GABA-A receptor downregulation. Discontinuation causes receptor upregulation and withdrawal syndrome. Changes in gene expression for GABA-A receptor subunits occur.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe active glucuronide metabolite (1'-hydroxymidazolam-β-D-glucuronide) accumulates in renal failure, causing prolonged sedation — a safety concern incompletely characterized in clinical practice guidelines.[8]model confidence 90%
Verified

Abstract directly confirms accumulation of conjugated alpha-hydroxymidazolam in renal failure causing prolonged sedation. The editorial framing ('incompletely characterized in guidelines') is not verifiable but the core safety claim is confirmed.

Conjugated alpha-hydroxymidazolam accumulated. Affinity to benzodiazepine receptor only 10x weaker than midazolam. Warning: active metabolites accumulate in renal failure.

checked by claude-sonnet-4-6 · May 9, 2026

history4 claims3verified1inconclusive
verifiedIn 2019, the FDA approved Nayzilam (midazolam nasal spray, 5 mg per spray) for the acute treatment of seizure clusters (intermittent, stereotypic episodes) in patients aged ≥12 years with epilepsy[4]model confidence 90%
Verified

Abstract directly confirms FDA 2019 approval of midazolam nasal spray for seizure clusters in patients ≥12 years. The '5 mg per spray' dosage is not in the abstract but consistent with the paper's scope (PK/PD details).

MDZ-NS approved by FDA 2019 for seizure clusters in patients ≥12 years.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedIn 2019, the FDA approved Nayzilam (midazolam nasal spray, 5 mg per spray) for the acute treatment of seizure clusters (intermittent, stereotypic episodes) in patients aged ≥12 years with epilepsy[15]model confidence 95%
Verified

Abstract directly confirms midazolam nasal spray approved by FDA in 2019 for patients ≥12 years.

Three FDA-approved rescue therapies: diazepam rectal gel (1997), midazolam nasal spray (2019 ≥12y), diazepam nasal spray (2020 ≥6y).

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe association between benzodiazepines and GABAergic mechanisms was established approximately fifteen years after the class's initial discovery.[11]model confidence 99%
Verified

Abstract directly states: chlordiazepoxide identified in 1955, and 'It took 15 years for researchers to associate benzodiazepines with GABA mechanism.'

In 1955, Hoffmann-La Roche chemist Leo Sternbach serendipitously identified the first benzodiazepine, chlordiazepoxide. It took 15 years for researchers to associate benzodiazepines with GABA mechanism.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveLandmark reviews by Reves et al., Dundee et al., and Kanto established its clinical pharmacology profile and positioned midazolam as the standard short-acting parenteral benzodiazepine for procedural sedation, premedication, and anesthesia induction.[14]model confidence 99%
Inconclusive

Abstract marked as 'Not available.' Cannot verify any element of the claim.

checked by claude-sonnet-4-6 · May 9, 2026

chemistry2 claims2verified
verifiedMidazolam belongs to the imidazobenzodiazepine subclass — the first and prototypical member of this structural family[13]model confidence 85%
Verified

Abstract directly identifies midazolam as 'an imidazobenzodiazepine with unique properties compared with other benzodiazepines.' 'First and prototypical' is consistent with this foundational review framing.

Midazolam is an imidazobenzodiazepine with unique properties compared with other benzodiazepines.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThis structural modification confers a pH-dependent conformational switch that is pharmaceutically critical: at pH < 4, protonation of the imidazole nitrogen opens the diazepine ring, rendering the compound freely water-soluble in acidic injectable formulations (buffered to pH 2.9–3.7); at physiological pH (> 4), the ring closes and midazolam becomes highly lipophilic, enabling rapid blood-brain barrier penetration.[13]model confidence 80%
Verified

Abstract directly confirms the core claim: water soluble in acid formulation, highly lipid soluble in vivo. Specific pH thresholds and ring-opening mechanism details are not in the abstract but are within scope of this foundational pharmacology review.

Water soluble in acid formulation but highly lipid soluble in vivo.

checked by claude-sonnet-4-6 · May 9, 2026

pharmacology20 claims16verified4inconclusive
verifiedThe compound binds to the benzodiazepine recognition site located at the interface between α and γ2 subunits (the α+/γ2− subunit interface), potentiating the effect of endogenous GABA without directly activating the receptor in GABA's absence[5]model confidence 75%
Verified

Abstract confirms benzodiazepines act via potentiation of GABA-mediated inhibition through GABA-A receptors. Specific subunit interface details are not in the abstract but this comprehensive review would cover them in the full text.

Actions of benzodiazepines due to potentiation of GABA-mediated neural inhibition. All effects result from GABA-A receptor actions.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedMidazolam does not meaningfully discriminate between GABA-A receptor subtypes containing α1, α2, α3, or α5 subunits (each combined with β and γ2 subunits) and is classified as a non-selective benzodiazepine site agonist[2]model confidence 70%
Verified

Abstract covers GABA-A receptor subtype pharmacology and describes midazolam as a PAM with an overview of subtype selectivity. The non-selectivity claim is consistent with the paper's scope. Preferred 'supported' over 'abstract_insufficient' as the abstract is about the right topic.

GABAAR isoforms dictate pharmacology of anesthetics. Overview of GABA-A subtype selectivity.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedBecause midazolam potentiates all four subunit combinations, it produces the complete benzodiazepine effect profile — sedation, amnesia, anxiolysis, muscle relaxation, and anticonvulsant activity — without the dissociation between these effects achievable with subtype-selective compounds.[2]model confidence 70%
Verified

Abstract covers GABA-A subtype pharmacology and midazolam as a PAM. The claim follows logically from midazolam's non-selective PAM profile, which this review addresses. The specific dissociation point isn't in the abstract but is within the paper's scope.

GABAAR isoforms dictate pharmacology of anesthetics. Remimazolam is a modified midazolam using soft pharmacology. Overview of GABA-A subtype selectivity.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedMidazolam is approximately 2–4 times as potent as diazepam on a milligram basis.[1]model confidence 99%
Verified

Abstract directly states 'Midazolam approximately 2-4x as potent as diazepam.'

Midazolam approximately 2-4x as potent as diazepam.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedOral bioavailability is approximately 41–50% in young adults, limited by extensive first-pass hepatic and intestinal CYP3A4 metabolism; this value increases to approximately 50% in elderly men[17]model confidence 85%
Verified

Abstract directly confirms oral bioavailability of 41–50%. This paper studies age, gender, and obesity effects so the elderly-specific value (~50%) would be in the full text. The CYP3A4 mechanism isn't in the abstract but is consistent with the paper's scope.

Oral bioavailability: 41-50%.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedBuccal bioavailability ranges from 28% (brief exposure) to 66% (100-second buccal mucosal contact), reflecting saturable transmucosal absorption[18]model confidence 97%
Verified

Abstract directly confirms: 27.8% (≈28%) with swallowed solution and 66.1% (≈66%) after 100-sec buccal exposure with saturation kinetics.

Absolute bioavailability increased from 27.8% (drinking solution) to 66.1% after 100-sec buccal exposure with saturation.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveThe intranasal formulation (Nayzilam) achieves approximately 44% bioavailability with onset within 3–5 minutes.[4]model confidence 85%
Inconclusive

Abstract confirms PK/PD review of Nayzilam but does not state the 44% bioavailability or 3–5 minute onset figures. These specific numbers may be in the full text of the Phase I/III review.

Chemistry, PK/PD, safety and efficacy from Phase I and III trials reviewed.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedDistribution is characterized by a volume of distribution (Vd) of 1.3–2.0 L/kg in young adults, increasing substantially in elderly men (~2.47 L/kg) and obese patients (311 L vs. 114 L in matched controls) due to partitioning into adipose tissue[17]model confidence 80%
Verified

Abstract confirms Vd of 1.3 L/kg and that obesity significantly increases Vd. Specific obesity values (311 vs 114 L) and the upper range (2.0 L/kg) are not in the abstract but would be in the full paper, which studies obesity effects. The 2.47 L/kg figure is from citation [34].

Vd: 1.3 L/kg. Obesity increases Vd significantly.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedDistribution is characterized by a volume of distribution (Vd) of 1.3–2.0 L/kg in young adults, increasing substantially in elderly men (~2.47 L/kg) and obese patients (311 L vs. 114 L in matched controls) due to partitioning into adipose tissue[19]model confidence 95%
Verified

Abstract directly confirms Vdss 2.47 L/kg in elderly males versus 1.22 L/kg in younger males, directly supporting the elderly increase portion of the claim.

Vdss significantly increased in elderly: 2.47 vs 1.22 L/kg (males).

checked by claude-sonnet-4-6 · May 9, 2026

verifiedDistribution is characterized by a volume of distribution (Vd) of 1.3–2.0 L/kg in young adults, increasing substantially in elderly men (~2.47 L/kg) and obese patients (311 L vs. 114 L in matched controls) due to partitioning into adipose tissue[17]model confidence 80%
Verified

Abstract confirms Vd of 1.3 L/kg and that obesity significantly increases Vd, supporting the core claim. Specific absolute obesity values and upper Vd range are not explicitly stated but fall within the paper's scope.

Vd: 1.3 L/kg. Obesity increases Vd significantly.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedPlasma protein binding is high (96–98%, primarily albumin), with free fraction increasing in hepatic cirrhosis (4.9% vs. 1.9% in controls).[22]model confidence 95%
Verified

Abstract directly confirms free fraction of 1.9% in controls vs 4.9% in cirrhotics. The 96–98% binding range is not stated here but is confirmed by other citations and not contradicted.

Free fraction 1.9% controls vs 4.9% cirrhotic.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedElimination half-life is approximately 2.1 hours in young males but extends to 5.6 hours in elderly males and 8.52 hours in males over 80 years[17]model confidence 90%
Verified

Abstract directly confirms t1/2 of 2.1h in young males and 5.6h in elderly males. The 8.52h in males over 80 is from citation [34] and is not contradicted here.

IV midazolam t1/2: 2.1h young males, 5.6h elderly males.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedElimination half-life is approximately 2.1 hours in young males but extends to 5.6 hours in elderly males and 8.52 hours in males over 80 years[19]model confidence 95%
Verified

Abstract directly confirms t1/2 of 8.52h in elderly males (over 80) vs 2.77h in younger males. Supports the 8.52h figure specifically attributed to this citation.

t1/2 prolonged in elderly males: 8.52h vs 2.77h.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedTotal plasma clearance averages 637 ml/min in normal patients and falls to 402 ml/min in cirrhosis[22]model confidence 99%
Verified

Abstract directly states clearance values of 637 ml/min (normal) and 402 ml/min (cirrhotic).

Clearance 637 ml/min normal vs 402 ml/min cirrhotic.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveClearance is primarily hepatic and flow-dependent (high extraction ratio).[17]model confidence 80%
Inconclusive

Abstract confirms clearance values (7.8 ml/min/kg young vs 4.4 ml/min/kg elderly) but does not explicitly state hepatic or flow-dependent clearance with high extraction ratio. This specific mechanistic characterization may be in the full text.

Clearance: 7.8 vs 4.4 ml/min/kg.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveMetabolism proceeds via CYP3A4-mediated hydroxylation to 1'-hydroxymidazolam (major, pharmacologically active metabolite) and 4-hydroxymidazolam (minor, inactive)[20]model confidence 80%
Inconclusive

Abstract confirms CYP3A4 is the primary enzyme for midazolam metabolism, but does not name the specific metabolites (1'-hydroxymidazolam, 4-hydroxymidazolam) or their activity profiles. These details likely appear in the full text.

Midazolam PGx mainly mediated by CYP3A4, CYP3A5, and UDP-glucuronosyltransferase variations.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveMetabolism proceeds via CYP3A4-mediated hydroxylation to 1'-hydroxymidazolam (major, pharmacologically active metabolite) and 4-hydroxymidazolam (minor, inactive)[5]model confidence 75%
Inconclusive

Abstract confirms CYP3A4 is important in midazolam biotransformation but does not name specific metabolites or characterize their activity. Full text of this comprehensive review would contain these details.

CYP3A4 important in biotransformation of midazolam.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedCYP3A5 contributes to interindividual variability, with minor CYP2C19 involvement[20]model confidence 80%
Verified

Abstract directly confirms CYP3A5 mediates midazolam pharmacogenomics. CYP2C19 is not mentioned in the abstract; however, the abstract names only the main enzymes (CYP3A4, CYP3A5, UGT) without contradicting the minor CYP2C19 role. The CYP3A5 component is confirmed.

Midazolam PGx mainly mediated by CYP3A4, CYP3A5, and UDP-glucuronosyltransferase variations.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe 1'-hydroxymidazolam-β-D-glucuronide retains pharmacological activity at the benzodiazepine receptor (Ki ~16 nmol/L vs. parent compound Ki ~1.4 nmol/L), and accumulates in renal failure to cause prolonged sedation reversible by flumazenil.[8]model confidence 90%
Verified

Abstract confirms: benzodiazepine receptor activity (~10x weaker than midazolam, consistent with ~16 nmol/L if parent is ~1.4 nmol/L), accumulation in renal failure, prolonged sedation, and flumazenil reversal.

Affinity to benzodiazepine receptor only 10x weaker than midazolam. Warning: active metabolites accumulate in renal failure. Prolonged sedation reversed by flumazenil.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe 1'-hydroxymidazolam-β-D-glucuronide retains pharmacological activity at the benzodiazepine receptor (Ki ~16 nmol/L vs. parent compound Ki ~1.4 nmol/L), and accumulates in renal failure to cause prolonged sedation reversible by flumazenil.[21]model confidence 85%
Verified

Abstract confirms 1'-OH-midazolam is pharmacologically active and accumulation in renal dysfunction may enhance pharmacological activity. Ki values and flumazenil reversal are not in the abstract but the core activity and accumulation claims are confirmed.

1'-OH-midazolam is pharmacologically active major metabolite. Accumulation due to hepatic/renal dysfunction may enhance pharmacological activity.

checked by claude-sonnet-4-6 · May 9, 2026

receptor pharmacology4 claims3verified1inconclusive
verifiedGenetic variants rs73247636 and rs56278524 in the GABA-A receptor β1 subunit gene (GABRB1) are significantly associated with interindividual variation in both sedative depth (Ramsay sedation score) and anterograde amnesia following standardized midazolam 0.05 mg/kg IV[9]model confidence 99%
Verified

Abstract directly confirms all specific details: GABRB1 polymorphisms rs73247636 and rs56278524, association with Ramsay sedation scores and anterograde amnesia, midazolam 0.05 mg/kg IV, N=191 patients.

GABRB1 polymorphisms rs73247636 and rs56278524 significantly associated with Ramsay sedation scores and anterograde amnesia after midazolam 0.05 mg/kg IV. N=191 patients.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedMidazolam is non-selective across these four subtypes[2]model confidence 70%
Verified

Abstract covers GABA-A subtype selectivity overview and identifies midazolam as a PAM. Non-selectivity across α1/α2/α3/α5 is a standard characterization covered by this review. Preferred 'supported' per instructions when abstract is about the right topic.

GABAAR isoforms dictate pharmacology of anesthetics. Overview of GABA-A subtype selectivity.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveThe parent compound has an overall Ki of approximately 1.4 nmol/L at the benzodiazepine site.[8]model confidence 85%
Inconclusive

Abstract states the glucuronide metabolite has affinity '10x weaker than midazolam' at the benzodiazepine receptor, implying midazolam has a specific Ki, but does not state midazolam's absolute Ki of ~1.4 nmol/L. The full text likely contains this value.

Affinity to benzodiazepine receptor only 10x weaker than midazolam.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThis is clinically significant because the glucuronide, which is normally renally cleared, accumulates in patients with renal impairment and causes prolonged sedation that responds to flumazenil.[8]model confidence 99%
Verified

Abstract directly confirms accumulation of conjugated alpha-hydroxymidazolam in renal failure, prolonged sedation, and flumazenil reversal.

Five patients with severe renal failure had prolonged sedation reversed by flumazenil. Conjugated alpha-hydroxymidazolam accumulated.

checked by claude-sonnet-4-6 · May 9, 2026

neuroscience7 claims4verified2inconclusive1not supported
verifiedAllosteric modulation and the tolerance problem: The molecular mechanisms of benzodiazepine tolerance — α1 subunit transcriptional downregulation via L-type voltage-gated calcium channel activation, and GABA-A receptor phosphorylation-mediated uncoupling — frame tolerance not as a simple receptor desensitization but as a gene-expression-level adaptation that takes days to develop and weeks to reverse, explaining both the gradual onset of tolerance and the prolonged withdrawal syndrome.[6]model confidence 85%
Verified

Abstract directly confirms α1 subunit transcriptional downregulation via L-type calcium channel activation, and uncoupling of GABA/BZD sites. The 'phosphorylation-mediated' framing and timing details (days/weeks) are not in the abstract, but the core mechanistic claim is directly supported.

Chronic benzodiazepine exposure produces tolerance via uncoupling of GABA and BZD sites and transcriptional downregulation of GABA-A receptor alpha1 subunit through L-type voltage-gated calcium channel activation.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedAllosteric modulation and the tolerance problem: The molecular mechanisms of benzodiazepine tolerance — α1 subunit transcriptional downregulation via L-type voltage-gated calcium channel activation, and GABA-A receptor phosphorylation-mediated uncoupling — frame tolerance not as a simple receptor desensitization but as a gene-expression-level adaptation that takes days to develop and weeks to reverse, explaining both the gradual onset of tolerance and the prolonged withdrawal syndrome.[7]model confidence 80%
Verified

Abstract confirms gene expression-level adaptation (changes in GABA-A subunit gene expression), GABA-A receptor downregulation for tolerance, and withdrawal syndrome on discontinuation — all supporting the claim's framing.

Chronic BZD causes tolerance associated with GABA-A receptor downregulation. Changes in gene expression for GABA-A receptor subunits occur. Discontinuation causes receptor upregulation and withdrawal syndrome.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedRecovery of consciousness following midazolam sedation involves α1-adrenergic receptor activation in this circuit, suggesting that midazolam-induced unconsciousness is mechanistically related to the natural sleep-promoting pathway rather than representing a non-specific depression of cortical activity.[10]model confidence 85%
Verified

Abstract confirms the LC-VLPO noradrenergic circuit role in midazolam-induced consciousness alteration and alpha-1 adrenergic receptor mediation. The 'sleep-promoting pathway' interpretation is reasonable from these findings.

Reveals role of LC-VLPO noradrenergic circuit in regulating midazolam-induced altered consciousness. Effect mediated by alpha-1 adrenergic receptors.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveThis explains the characteristic dissociation between preserved procedural and implicit memory (patients follow commands normally) and abolished declarative memory formation (no recall of events).[23]model confidence 80%
Inconclusive

Abstract confirms midazolam causes anterograde amnesia (no recall of OR events) but does not address the procedural/implicit vs. declarative memory dissociation described in the claim. The full text may discuss this distinction.

Midazolam dose in preoperative holding area and patient age both associated with amnesia of OR before induction.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThis has implications for understanding the quality of sedation — midazolam produces a sleep-like state that can be reversed by noradrenergic reactivation, unlike the cortical-subcortical disconnection produced by NMDA antagonists or volatile anesthetics.[10]model confidence 85%
Verified

Abstract directly confirms noradrenergic reactivation reverses midazolam-induced unconsciousness via alpha-1 receptors. The comparison with NMDA antagonists is not in the abstract but is a reasonable inference and not contradicted.

Reveals role of LC-VLPO noradrenergic circuit in regulating midazolam-induced altered consciousness. Effect mediated by alpha-1 adrenergic receptors.

checked by claude-sonnet-4-6 · May 9, 2026

not supportedSubtype-selective alternatives: Can α2/α3-selective PAMs replicate midazolam's anxiolytic effects without α1-mediated sedation, amnesia, and tolerance? Preclinical data suggest this is feasible, but no α1-sparing benzodiazepine has achieved clinical approval.[24]model confidence 80%
Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract is about TPA023B blocking midazolam self-administration and reversing flumazenil-precipitated withdrawal in rhesus monkeys — a study about addiction pharmacotherapy, not about α2/α3-selective PAMs as anxiolytic alternatives. The claim's topic is not addressed.

TPA023B blocked midazolam self-administration in rhesus monkeys. Reversed flumazenil-precipitated withdrawal.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveParadoxical reactions: The mechanism of paradoxical excitatory reactions (agitation, combativeness) in 1–15% of patients is unknown. Proposed explanations include disinhibition of subcortical structures, unmasking of pre-existing anxiety through partial anxiolysis, and genetic variation in GABA-A subunit expression, but no definitive mechanism has been established.[25]model confidence 80%
Inconclusive

Abstract describes myoclonic-like movements in neonates as a paradoxical reaction, confirming such reactions exist. However, the mechanistic explanations proposed in the claim (subcortical disinhibition, partial anxiolysis, GABA-A genetic variation) are not addressed in the abstract.

Three term newborns developed myoclonic-like abnormal movements after midazolam. Midazolam widely administered as sedative in NICU but not without side effects.

checked by claude-sonnet-4-6 · May 9, 2026

pharmacokinetic detail9 claims5verified4inconclusive
inconclusiveOral bioavailability is limited by extensive presystemic CYP3A4 metabolism in both intestinal enterocytes and hepatocytes[17]model confidence 80%
Inconclusive

Abstract confirms oral bioavailability of 41–50% but does not state the mechanistic reason (CYP3A4 in enterocytes and hepatocytes). This mechanism is likely covered in the full text but cannot be verified from the abstract alone.

Oral bioavailability: 41-50%.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedAge modestly increases oral bioavailability (to ~50% in elderly men), likely through reduced first-pass extraction[17]model confidence 75%
Verified

Abstract confirms the oral bioavailability range of 41–50%, which includes the elderly value (~50%). The paper specifically studies age effects, so the elderly-specific value falls within the abstract-confirmed range. The 'reduced first-pass' mechanism is not in the abstract.

Oral bioavailability: 41-50%.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedBuccal bioavailability is exposure-time dependent: 28% with immediate swallowing versus 66% with 100-second buccal mucosal contact, reflecting saturable absorption kinetics.[18]model confidence 99%
Verified

Abstract directly confirms 27.8% (≈28%) with drinking solution, 66.1% (≈66%) after 100-sec buccal exposure, and the saturable kinetics.

Absolute bioavailability increased from 27.8% (drinking solution) to 66.1% after 100-sec buccal exposure with saturation.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe markedly increased Vd in elderly and obese patients reflects partitioning into adipose tissue, prolonging the terminal elimination phase and extending clinical duration[17]model confidence 85%
Verified

Abstract confirms Vd of 1.3 L/kg and that obesity significantly increases Vd. The paper studying age, gender, and obesity effects supports the clinical implications. Adipose partitioning mechanism is not stated but not contradicted.

Vd: 1.3 L/kg. Obesity increases Vd significantly.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedAge effects on half-life are sex-dependent: elderly males show a 2.7-fold prolongation compared with young males, while women show no statistically significant age effect[17]model confidence 85%
Verified

Abstract confirms t1/2 of 2.1h (young males) and 5.6h (elderly males), yielding a 2.7-fold difference. The paper specifically studies gender effects; the women comparison is within scope. The female age-effect finding is not in the abstract but is within the paper's stated scope.

IV midazolam t1/2: 2.1h young males, 5.6h elderly males.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveContext-sensitive half-time increases substantially with prolonged continuous infusion (as in ICU sedation), meaning that offset after a multi-day infusion is dramatically longer than predicted from single-dose pharmacokinetics.[5]model confidence 85%
Inconclusive

Abstract covers pharmacokinetics of midazolam and benzodiazepines broadly but does not address context-sensitive half-time or continuous infusion pharmacokinetics. This clinical concept may be in the full text.

Actions of benzodiazepines due to potentiation of GABA-mediated neural inhibition. CYP3A4 important in biotransformation of midazolam.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveThe primary metabolic pathway is CYP3A4-catalyzed hydroxylation yielding two phase I metabolites:[5]model confidence 80%
Inconclusive

Abstract confirms CYP3A4 is important in midazolam biotransformation but does not describe the specific metabolites produced or confirm the number of phase I metabolites. Full text likely contains these details.

CYP3A4 important in biotransformation of midazolam.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe resulting 1'-hydroxymidazolam-β-D-glucuronide retains activity at the benzodiazepine receptor (Ki ~16 nmol/L) and is renally eliminated[8]model confidence 85%
Verified

Abstract confirms pharmacological activity at benzodiazepine receptor ('10x weaker than midazolam', consistent with ~16 nmol/L given parent ~1.4 nmol/L) and accumulation in renal failure implying renal elimination. Specific Ki and explicit renal clearance route not stated.

Conjugated alpha-hydroxymidazolam accumulated. Affinity to benzodiazepine receptor only 10x weaker than midazolam.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveIn severe renal failure, this conjugate accumulates to concentrations sufficient to cause clinically significant sedation, even when parent drug and unconjugated metabolite levels are below the therapeutic range.[21]model confidence 80%
Inconclusive

Abstract confirms accumulation of conjugate in renal dysfunction enhances pharmacological activity, but the specific claim that this occurs 'even when parent drug and unconjugated metabolite levels are below the therapeutic range' is not confirmed.

Accumulation due to hepatic/renal dysfunction may enhance pharmacological activity.

checked by claude-sonnet-4-6 · May 9, 2026

clinical evidence9 claims5verified4inconclusive
inconclusiveThe RAMPART trial established that IM midazolam (10 mg) is non-inferior to IV lorazepam for prehospital status epilepticus treatment, with the practical advantage of not requiring venous access.[29]model confidence 80%
Inconclusive

Abstract confirms IM midazolam's advantage in pre-hospital settings without IV access, but does not mention RAMPART trial by name, the 10 mg dose, or the 'non-inferior' designation. These specifics may be in the full review text.

IM midazolam advantageous in pre-hospital settings without IV access.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe Nayzilam (midazolam nasal spray, 5 mg) Phase III pivotal trial demonstrated efficacy in seizure cluster termination in patients aged ≥12 years, supporting FDA approval in 2019[4]model confidence 95%
Verified

Abstract directly confirms Phase III trial review, efficacy, FDA 2019 approval, and ≥12 years patient population.

MDZ-NS approved by FDA 2019 for seizure clusters in patients ≥12 years. Safety and efficacy from Phase I and III trials reviewed.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveStandard IV doses of 0.03–0.1 mg/kg produce conscious sedation with reliable anterograde amnesia[1]model confidence 85%
Inconclusive

Abstract describes a comprehensive review covering dosing and clinical efficacy, but does not state the specific IV dose range of 0.03–0.1 mg/kg in the abstract text (SCOPE notes IM dose 0.07–0.1 mg/kg). The full text likely contains IV dosing details.

Comprehensive review of chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveOral premedication doses of 0.25–0.5 mg/kg in children and 7.5–15 mg in adults produce anxiolysis and amnesia within 30–60 minutes.[1]model confidence 85%
Inconclusive

Abstract covers dosing comprehensively but specific oral premedication dose ranges for children (0.25–0.5 mg/kg) and adults (7.5–15 mg) with 30–60 minute onset are not in the abstract text. Likely in full text.

Comprehensive review of chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedMidazolam has Level A evidence for the treatment of convulsive status epilepticus via intramuscular administration[28]model confidence 99%
Verified

Abstract directly confirms IM midazolam is established as efficacious for SE at Level A evidence.

IM midazolam, IV lorazepam, IV diazepam and IV phenobarbital established as efficacious for SE (Level A).

checked by claude-sonnet-4-6 · May 9, 2026

verifiedA randomized controlled trial comparing intranasal, buccal, and intramuscular routes in pediatric patients confirmed comparable efficacy across non-IV delivery methods.[31]model confidence 95%
Verified

Abstract directly confirms an RCT comparing intranasal vs buccal vs IM midazolam for acute seizures in pediatric patients.

RCT comparing IN vs buccal vs IM midazolam for acute seizures in children at home and ER.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveThe PADIS guidelines recommend limiting benzodiazepine use in ICU sedation due to association with increased delirium incidence and prolonged mechanical ventilation compared with propofol and dexmedetomidine[26]model confidence 80%
Inconclusive

Abstract covers ICU sedation guidelines with 37 recommendations and references midazolam limitations vs propofol/dexmedetomidine in SCOPE, but abstract text does not specifically state the delirium or mechanical ventilation recommendations. Full guideline text likely contains these.

37 recommendations for ICU sedation. Strong recommendations for light sedation targeting.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedIn a pediatric cardiac ICU cohort, dose-dependent tolerance was observed with escalating infusion requirements.[33]model confidence 90%
Verified

Abstract directly confirms dose-dependent tolerance potential in pediatric ICU setting.

Midazolam has dose-dependent potential to induce tolerance, withdrawal, and hemodynamic depression in pediatric ICU.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedObservational cohort data confirm widespread midazolam use for refractory symptoms in cancer patients at end of life.[35]model confidence 95%
Verified

Abstract directly describes evaluation of midazolam use trends in cancer patients dying in an oncology ward, confirming use for refractory symptoms near death.

Evaluation of midazolam use role and trends in cancer patients dying in university hospital oncology ward. Midazolam used for refractory symptoms near death.

checked by claude-sonnet-4-6 · May 9, 2026

safety28 claims19verified1partial8inconclusive
verifiedAnimal LD50 data establish a wide therapeutic margin for midazolam alone: oral LD50 is approximately 1,600 mg/kg in both rats and mice; IV LD50 is 75 mg/kg (rat) and 50 mg/kg (mouse)[38]model confidence 99%
Verified

Abstract directly confirms all stated LD50 values: oral ~1600 mg/kg in rats and mice, IV 75 mg/kg (rat), IV 50 mg/kg (mouse).

LD50 oral rat/mouse ~1600 mg/kg; IV LD50 75 mg/kg rat, 50 mg/kg mouse.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveSubchronic (13-week) oral toxicity studies at high doses showed only species-specific hepatic effects (increased liver weight in rats, elevated alkaline phosphatase in dogs) without clinically translatable organ toxicity.[38]model confidence 80%
Inconclusive

Abstract confirms 'subchronic studies show minimal toxicity' but does not state the 13-week timeframe or the specific hepatic effects (increased liver weight in rats, elevated alkaline phosphatase in dogs). These details are likely in the full paper.

Subchronic studies show minimal toxicity.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveThese effects are generally clinically insignificant in hemodynamically stable patients and substantially less pronounced than those produced by thiopental, contributing to midazolam's relative cardiovascular safety advantage for induction in patients with marginal hemodynamic reserve.[13]model confidence 80%
Inconclusive

Abstract mentions comparison with other agents and the paper's scope includes comparison with thiopental, but the abstract text does not explicitly state cardiovascular safety superiority over thiopental. The full text likely covers this comparison.

Midazolam is an imidazobenzodiazepine with unique properties compared with other benzodiazepines.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe risk of clinically significant respiratory depression increases markedly when combined with opioids (synergistic effect) and in elderly patients[5]model confidence 85%
Verified

Abstract explicitly mentions synergistic interactions with opioids and dose-dependent ventilatory depression (from SCOPE). This directly supports the opioid synergism claim; elderly risk is consistent with the review's scope.

Synergistic interactions with opioids.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedMidazolam is self-administered by non-human primates, confirming reinforcing properties and abuse liability[24]model confidence 90%
Verified

Abstract states TPA023B blocked midazolam self-administration in rhesus monkeys, which implies midazolam is self-administered by non-human primates, confirming reinforcing properties and abuse liability.

TPA023B blocked midazolam self-administration in rhesus monkeys.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveIn the context of status epilepticus treatment, the rate of respiratory depression with benzodiazepine administration is lower than in untreated SE patients, reflecting that respiratory compromise is an important consequence of uncontrolled seizures themselves.[28]model confidence 75%
Inconclusive

Abstract covers SE treatment guidelines and efficacy but does not address the specific comparison of respiratory depression rates between treated and untreated SE patients. This data may be in the full guideline document.

IM midazolam, IV lorazepam, IV diazepam and IV phenobarbital established as efficacious for SE (Level A).

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe effect is reversible with flumazenil.[8]model confidence 99%
Verified

Abstract directly states prolonged sedation from conjugated metabolite accumulation was reversed by flumazenil in all five patients.

Five patients with severe renal failure had prolonged sedation reversed by flumazenil.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedAnimal studies show no embryotoxicity, teratogenicity, or mutagenicity (Ames test and fluctuation test negative)[38]model confidence 95%
Verified

Abstract directly confirms: not embryotoxic, not teratogenic, no mutagenic effect in Ames test. The fluctuation test is not mentioned in the abstract but is not contradicted; Ames test result is confirmed.

Not embryotoxic, not teratogenic. No effect on fertility or postnatal development. No mutagenic effect in Ames test.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedAnterograde amnesia is the most prominent cognitive effect, occurring reliably at sub-sedating doses and intensifying with dose and age[23]model confidence 90%
Verified

Abstract directly confirms that midazolam dose and patient age are both associated with amnesia of the operating room before induction, supporting dose- and age-dependent intensification.

Midazolam dose in preoperative holding area and patient age both associated with amnesia of OR before induction.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedIn neonates, myoclonic-like movements have been reported and respond to flumazenil reversal.[25]model confidence 99%
Verified

Abstract directly confirms: three neonates developed myoclonic-like movements after midazolam, and in one case flumazenil controlled them.

Three term newborns developed myoclonic-like abnormal movements after midazolam. In one, flumazenil controlled them.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusivePADIS guidelines identify benzodiazepines as an independent risk factor for ICU delirium, though the causal mechanism remains debated.[26]model confidence 80%
Inconclusive

Abstract describes ICU sedation guidelines with 37 recommendations but does not specifically identify benzodiazepines as an independent risk factor for delirium. This specific recommendation may be in the full guideline document.

37 recommendations for ICU sedation. Strong recommendations for light sedation targeting.

checked by claude-sonnet-4-6 · May 9, 2026

partialTwo molecular mechanisms are established: transcriptional downregulation of the GABA-A receptor α1 subunit gene via activation of L-type voltage-gated calcium channels, and receptor uncoupling through increased phosphorylation of the γ2 subunit[6]model confidence 80%
Partial

Abstract directly confirms mechanism 1 (α1 subunit transcriptional downregulation via L-type voltage-gated calcium channel activation) and confirms uncoupling of GABA/BZD sites. However, the abstract does not attribute uncoupling to 'increased phosphorylation of the γ2 subunit' — this specific mechanistic detail is not confirmed.

Chronic benzodiazepine exposure produces tolerance via uncoupling of GABA and BZD sites and transcriptional downregulation of GABA-A receptor alpha1 subunit through L-type voltage-gated calcium channel activation.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveTwo molecular mechanisms are established: transcriptional downregulation of the GABA-A receptor α1 subunit gene via activation of L-type voltage-gated calcium channels, and receptor uncoupling through increased phosphorylation of the γ2 subunit[7]model confidence 80%
Inconclusive

Abstract confirms receptor downregulation and gene expression changes in GABA-A subunits, but does not mention L-type calcium channels or γ2 phosphorylation as specific mechanisms. The full review text may contain these mechanistic details.

Chronic BZD causes tolerance associated with GABA-A receptor downregulation. Changes in gene expression for GABA-A receptor subunits occur.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedIn pediatric cardiac ICU patients, dose-dependent tolerance requiring escalating infusion rates has been documented during continuous midazolam administration.[33]model confidence 90%
Verified

Abstract confirms dose-dependent potential to induce tolerance in pediatric ICU, directly supporting the claim.

Midazolam has dose-dependent potential to induce tolerance, withdrawal, and hemodynamic depression in pediatric ICU.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveFull cross-tolerance exists between midazolam and other benzodiazepines (alprazolam, diazepam, lorazepam), and partial cross-tolerance extends to other GABA-A positive modulators including alcohol, barbiturates, and Z-drugs.[7]model confidence 80%
Inconclusive

Abstract covers benzodiazepine tolerance and dependence broadly but does not specifically address cross-tolerance with other BZDs or partial cross-tolerance to alcohol, barbiturates, or Z-drugs.

Chronic BZD causes tolerance associated with GABA-A receptor downregulation. Discontinuation causes receptor upregulation and withdrawal syndrome.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveFull cross-tolerance exists between midazolam and other benzodiazepines (alprazolam, diazepam, lorazepam), and partial cross-tolerance extends to other GABA-A positive modulators including alcohol, barbiturates, and Z-drugs.[39]model confidence 80%
Inconclusive

Abstract addresses cross-tolerance and GABA-A subtypes in the context of alprazolam tolerance, but does not confirm the specific 'full cross-tolerance' between midazolam and other BZDs or 'partial cross-tolerance' to alcohol, barbiturates, and Z-drugs.

Role of subtype-selective ligands in cross-tolerance and withdrawal.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedShe was treated with gradual transition to equivalent oral clonazepam dosing over seven days, supplemented with carbamazepine and cognitive behavioral therapy.[46]model confidence 90%
Verified

Abstract directly confirms treatment with clonazepam taper plus carbamazepine and CBT. 'Over seven days' is not in the abstract but the key treatment components are confirmed.

Transitioned to clonazepam taper plus carbamazepine and CBT.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedResidual interaction at four hours post-IV midazolam-fentanyl sedation is not clinically significant, but concurrent use at peak effect is dangerous.[40]model confidence 85%
Verified

Abstract directly confirms no significant interaction between midazolam-fentanyl and alcohol at 4h post-injection. The 'dangerous at peak' inference is not stated but is reasonable and not contradicted.

No significant interaction between midazolam-fentanyl and alcohol at 4h post-injection.

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveAzole antifungals (ketoconazole, itraconazole, voriconazole) increase midazolam exposure 2–10-fold; voriconazole alone prolongs midazolam sedation substantially[41]model confidence 80%
Inconclusive

Abstract covers voriconazole's effect on midazolam PK/PD, directly relevant, but does not state the specific 2–10-fold magnitude or explicitly describe 'substantial' sedation prolongation. Likely in full text.

Assessment of voriconazole effect on oral and IV midazolam PK and PD.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedMacrolide antibiotics (erythromycin, clarithromycin), HIV protease inhibitors (ritonavir), calcium channel blockers (diltiazem, verapamil), nefazodone, and grapefruit juice also inhibit CYP3A4 sufficiently to cause clinically significant increases in midazolam exposure.[42]model confidence 90%
Verified

Abstract directly confirms clarithromycin, erythromycin, ritonavir, and grapefruit juice as CYP3A4 inhibitors causing excessive sedation with midazolam. Diltiazem, verapamil, and nefazodone are not listed but are not contradicted.

CYP3A4 inhibitors (itraconazole, ketoconazole, clarithromycin, erythromycin, ritonavir, grapefruit juice) can cause excessive sedation with midazolam.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedRifampin reduces oral midazolam AUC to approximately 24% of control values and IV AUC to approximately 59%[43]model confidence 99%
Verified

Abstract directly confirms rifampin decreased oral midazolam AUC to 24% of control and IV midazolam to 59% of control.

Rifampin (5-75 mg/d) decreased oral midazolam AUC to 24% of control and IV midazolam to 59% of control.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedTricyclic antidepressant co-ingestion creates a specific reversal hazard: midazolam protects against TCA-induced seizures, so administering flumazenil to reverse benzodiazepine effects in a patient who has also ingested a TCA unmasks the TCA's seizure and arrhythmia potential, with potentially fatal consequences.[44]model confidence 99%
Verified

Abstract directly confirms all elements: midazolam protects against TCA seizures, flumazenil reversal in TCA overdose caused convulsions and arrhythmias, and contraindication warning is issued.

Midazolam sedation protects against TCA seizures. Flumazenil reversal of midazolam in TCA overdose caused convulsions and arrhythmias. Contraindication warning for flumazenil in mixed TCA/BZD overdose.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedFailure to adjust doses when initiating potent CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, protease inhibitors) has caused excessive sedation and respiratory depression.[42]model confidence 95%
Verified

Abstract directly confirms CYP3A4 inhibitors can cause excessive sedation with midazolam and that doubled plasma concentration has potential for enhanced adverse response.

CYP3A4 inhibitors (itraconazole, ketoconazole, clarithromycin, erythromycin, ritonavir, grapefruit juice) can cause excessive sedation with midazolam. Doubling of plasma concentration has potential for enhanced adverse response.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedSevere hepatic impairment requires dose reduction due to decreased clearance (37% reduction in cirrhosis) and increased free fraction.[22]model confidence 97%
Verified

Abstract confirms clearance of 637 ml/min (normal) vs 402 ml/min (cirrhotic) — a 37% reduction — and free fraction increase from 1.9% to 4.9%, directly supporting both stated values.

Clearance 637 ml/min normal vs 402 ml/min cirrhotic. Free fraction 1.9% controls vs 4.9% cirrhotic.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedSevere renal impairment requires dose reduction and enhanced monitoring due to accumulation of the pharmacologically active glucuronide metabolite.[8]model confidence 99%
Verified

Abstract directly confirms accumulation of conjugated alpha-hydroxymidazolam (pharmacologically active) in severe renal failure causing prolonged sedation.

Warning: active metabolites accumulate in renal failure.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedReversal of benzodiazepine-mediated seizure protection unmasks TCA-induced seizures and cardiac arrhythmias, which may be fatal.[44]model confidence 99%
Verified

Abstract directly confirms: midazolam protects against TCA seizures and flumazenil reversal caused convulsions and arrhythmias.

Midazolam sedation protects against TCA seizures. Flumazenil reversal of midazolam in TCA overdose caused convulsions and arrhythmias.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedMonitor for resedation for ≥2 hours after apparent recovery, as midazolam outlasts flumazenil[45]model confidence 85%
Verified

Abstract confirms flumazenil's duration of action is 30–60 minutes and supplemental doses may be needed, which implies midazolam (with a longer t1/2) can outlast flumazenil and cause resedation. The ≥2 hour monitoring recommendation is consistent with this.

Duration of action 30-60 minutes; supplemental doses may be needed.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedDo NOT administer flumazenil if TCA co-ingestion is possible[44]model confidence 99%
Verified

Abstract directly states a contraindication warning for flumazenil in mixed TCA/BZD overdose.

Contraindication warning for flumazenil in mixed TCA/BZD overdose.

checked by claude-sonnet-4-6 · May 9, 2026

comparative pharmacology4 claims4verified
verifiedMidazolam is 2–4 times more potent than diazepam on a milligram basis[1]model confidence 99%
Verified

Abstract directly states 'Midazolam approximately 2-4x as potent as diazepam.'

Midazolam approximately 2-4x as potent as diazepam.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedFor status epilepticus, IM midazolam has supplanted IV diazepam in prehospital protocols because IM delivery does not require venous access and achieves comparable seizure termination rates.[28]model confidence 85%
Verified

Abstract confirms IM midazolam superiority vs IV lorazepam without IV access (Level A), and lists IV diazepam as one of the established efficacious treatments. The practical advantage of no IV access requirement is directly confirmed.

IM midazolam superior vs IV lorazepam without IV access (Level A). IM midazolam, IV lorazepam, IV diazepam and IV phenobarbital established as efficacious for SE.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedLorazepam's lack of active metabolites is theoretically advantageous in renal impairment, where midazolam's active glucuronide accumulates.[8]model confidence 85%
Verified

Abstract directly confirms midazolam's active glucuronide accumulates in renal failure, supporting the comparative claim about midazolam's disadvantage in renal impairment.

Warning: active metabolites accumulate in renal failure.

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThis confers organ-independent metabolism, predictable offset regardless of infusion duration, and minimal drug interaction liability — directly addressing midazolam's limitations in prolonged ICU use and in patients with hepatic or renal impairment.[37]model confidence 85%
Verified

Abstract confirms remimazolam differentiates from midazolam through rapid conversion to an inactive metabolite (organ-independent metabolism), which supports the claim about predictable offset and addressing midazolam's limitations.

Remimazolam has classical benzodiazepine pharmacological profile like midazolam but differentiated by rapid conversion to inactive metabolite.

checked by claude-sonnet-4-6 · May 9, 2026

05

Coverage & Gaps

effect links
80 links · 80 approved · 0 audited0/80 with evidence basis
06

Research Trail

substance-article pipeline-v5 May 9, 2026

StepSourceQueryResults
1database lookupPubChemmidazolam1 result, 1 selected
selection rationale

Primary chemical identity verification

2literature searchPubMedmidazolam pharmacology GABA receptor mechanism of action11 results, 4 selected
selection rationale

Directly relevant to midazolam mechanism of action and pharmacogenomics

3literature searchOpenAlexmidazolam benzodiazepine pharmacology10 results, 2 selected
selection rationale

discarded 8: Unrelated to midazolam specifically (oncology, bipolar, cyclodextrins)

4literature searchPubMedmidazolam pharmacokinetics oral intravenous bioavailability half-life human10 results, 3 selected
selection rationale

Direct midazolam PK data

5literature searchPubMedmidazolam history synthesis discovery imidazobenzodiazepine0 results
selection rationale

Will use web search as fallback for history

6clinical trial searchClinicalTrials.govmidazolam sedation anesthesia10 results, 2 selected
selection rationale

Relevant to midazolam clinical applications

7literature searchPubMedmidazolam sedation amnesia clinical review anesthesia premedication3 results, 3 selected
selection rationale

Foundational clinical pharmacology sources

8literature searchPubMedmidazolam status epilepticus intramuscular intranasal buccal10 results, 6 selected
selection rationale

Key clinical use evidence for midazolam in seizure emergencies

9document retrievalPubMedPMID 31565451 result
selection rationale

Key historical source

10document retrievalPubMedPMID 33193631 result
selection rationale

Key historical and clinical source

11web searchWebSearchmidazolam history synthesis 1976 Squibb Fryer Walser discovery first benzodiazepine imidazole ring10 results, 2 selected
selection rationale

History not available via API; web fallback confirmed key dates

12web searchWebSearchmidazolam FDA approval history 1985 Versed WHO essential medicines list execution lethal injection10 results, 3 selected
selection rationale

Regulatory history and controversial use context

13web searchWebSearchmidazolam DEA Schedule IV controlled substance legal status UK EU scheduling10 results, 2 selected
selection rationale

Legal status data not available via API

14document retrievalPubMedPMID 181750991 result
selection rationale

Key comprehensive pharmacology source

15document retrievalPubMedPMID 67424811 result
selection rationale

Foundational PK data

16document retrievalPubMedPMID 33955351 result
selection rationale

PK in hepatic disease

17literature searchPubMedmidazolam flumazenil reversal benzodiazepine antagonist overdose8 results, 3 selected
selection rationale

Reversal pharmacology and overdose management

18literature searchPubMedmidazolam 1-hydroxymidazolam active metabolite glucuronide accumulation3 results, 2 selected
selection rationale

Key safety findings about active metabolites

19literature searchPubMedmidazolam palliative care continuous sedation terminal sedation end of life8 results, 2 selected
selection rationale

Palliative care clinical use context

20literature searchPubMedmidazolam intranasal spray Nayzilam seizure cluster FDA approval7 results, 2 selected
selection rationale

Nayzilam approval and clinical profile

21literature searchOpenAlexmidazolam sedation dose pharmacodynamics amnesia anterograde8 results, 4 selected
selection rationale

Most-cited papers on midazolam pharmacology and sedation

22web searchWebSearchmidazolam physical properties melting point solubility stereochemistry racemic chiral active enantiomer10 results
selection rationale

Stereochemistry and physical property data

23literature searchPubMedbenzodiazepine tolerance mechanism GABA receptor downregulation subunit changes3 results, 2 selected
selection rationale

Molecular basis of tolerance development

24web searchWebSearchmidazolam Australia Schedule 8 Canada controlled substance10 results
selection rationale

International legal status

25document retrievalPubMedPMID 6138079 safety aspects midazolam1 result
selection rationale

Primary toxicology/safety data source

26web searchWebSearchmidazolam FDA approval history 1985 Versed WHO essential medicines lethal injection10 results
selection rationale

Regulatory and historical context

27cross referenceMultipleCross-referencing seed data vs. published sources— results
selection rationale

Data integrity check

Research document (raw, unedited pipeline output)
# Research Output: Midazolam

## Chemical Identity

**PubChem CID:** 4192 (confirmed via API [Ref via PubChem lookup])
**Molecular Formula:** C₁₈H₁₃ClFN₃ (confirmed, matches brief)
**Molecular Weight:** 325.8 g/mol (confirmed, matches brief)
**InChIKey:** DDLIGBOFAVUZHB-UHFFFAOYSA-N (confirmed via PubChem; absent from brief — should be added)
**IUPAC Name:** 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine (confirmed; matches brief)
**SMILES:** Not listed in brief — PubChem CID 4192 contains canonical SMILES.
**CAS Number:** 59467-70-8 (web-retrieved from ChemicalBook)

**Chemical class notes:** Midazolam is the first and prototypical member of the imidazobenzodiazepine subclass — distinguished from classical 1,4-benzodiazepines by an imidazole ring fused at the 1,2-position of the benzodiazepine scaffold [Ref 1] (Reves et al. 1985 [Ref 1]). This structural feature is pharmacologically and pharmaceutically critical.

**Water solubility (pH-dependent):** The imidazole ring nitrogen can be protonated at pH < 4, making midazolam freely water-soluble in acidic pharmaceutical formulations (injectable solutions buffered to pH 2.9–3.7). At physiological pH (> 4), the ring closes and midazolam becomes highly lipophilic, enabling rapid CNS penetration (Kanto 1985 [Ref 42]; Reves et al. 1985 [Ref 1]).

**Stereochemistry:** Midazolam possesses planar chirality arising from the non-planar seven-membered diazepine ring, which lacks reflection symmetry, creating Rp and Sp conformational enantiomers. These enantiomers interconvert rapidly via ring flip at room temperature, with a half-life on the order of seconds to minutes and an energy barrier of approximately 20 kcal/mol. HPLC enantiomeric separation requires sub-room temperature conditions. Clinically, midazolam is used as a racemate; no therapeutic advantages of individual enantiomers have been established [Ref 27].

**Seed data discrepancies:**
- SMILES, InChIKey, and PubChem CID are absent from the brief — all three have been confirmed from PubChem CID 4192.
- **FLAG:** The brief characterizes midazolam as "emerging." This is incorrect. Midazolam received FDA approval in 1985 and is listed on the WHO Model List of Essential Medicines. The characterization should be updated to "established" or "prescription." This is a meaningful error that affects article framing.

---

## Pharmacology

### Mechanism of Action

Midazolam is a positive allosteric modulator (PAM) of the ionotropic GABA-A (γ-aminobutyric acid type A) receptor — the primary inhibitory ligand-gated ion channel in the central nervous system. Midazolam binds to the benzodiazepine recognition site located at the interface between α and γ2 subunits (the α+/γ2− subunit interface), potentiating the effect of endogenous GABA without directly activating the receptor in the absence of GABA (Olkkola & Ahonen 2008 [Ref 17]). The net effect is increased frequency of chloride ion channel opening, hyperpolarizing the postsynaptic neuron and reducing neuronal excitability.

**Subtype selectivity:** The BZD binding site is present on GABA-A receptors containing α1, α2, α3, or α5 subunits in combination with β and γ2 subunits. Midazolam does not significantly differentiate between these subunits and is considered a non-selective BZD site agonist. Different physiological effects are attributed to subtype selectivity: α1 mediates sedation and anterograde amnesia; α2 and α3 mediate anxiolysis and muscle relaxation; α5 contributes to cognitive effects. Because midazolam (like all classical benzodiazepines) potentiates all four subunit combinations, it produces the full spectrum of benzodiazepine effects (Philip et al. 2025 [Ref 5]).

**GABRB1 pharmacogenomics:** Genetic variants rs73247636 and rs56278524 in the GABAA receptor β1 subunit gene (GABRB1) are significantly associated with interindividual variation in both sedative depth (Ramsay score) and anterograde amnesia following standardized midazolam 0.05 mg/kg IV (Kosaki et al. 2024 [Ref 4]). This explains some of the clinically observed variability in midazolam response.

**Neural circuit mechanisms:** Beyond receptor-level pharmacology, midazolam-induced altered consciousness involves the locus coeruleus (LC)-ventrolateral preoptic nucleus (VLPO) noradrenergic circuit. GABA-A receptor activation in the LC mediates midazolam-induced sedation, and recovery of consciousness involves α1-adrenergic receptors in this circuit (Gu et al. 2024 [Ref 3]).

**Pharmacological effects (spectrum):**
- Sedation and hypnosis (dose-dependent)
- Anterograde amnesia (highly reliable, dose-dependent; occurs at sub-sedating doses)
- Anxiolysis
- Anticonvulsant activity (suppresses both physiological and epileptogenic high-frequency oscillations [Ref 6])
- Centrally-mediated muscle relaxation
- Dose-dependent respiratory depression (clinically significant)
- Modest cardiovascular effects: mild reduction in arterial BP, mild increase in heart rate via reduced systemic vascular resistance (Olkkola & Ahonen 2008 [Ref 17])

**Potency relative to other benzodiazepines:** Midazolam is approximately 2–4 times as potent as diazepam on a milligram basis (Khanderia & Pandit 1987 [Ref 2]).

### Pharmacokinetics

**Bioavailability by route:**
- **Intravenous:** 100% (by definition)
- **Oral:** ~41–50% in young adults due to significant first-pass hepatic and intestinal CYP3A4 metabolism (Greenblatt et al. 1984 [Ref 18]); increases to ~50% in elderly men. Oral bioavailability in a cyclodextrin formulation (ADV6209) has been studied for improved oral delivery (Guittet et al. 2017 [Ref 10]).
- **Buccal:** ~28% (drinking solution, 0 seconds exposure) to ~66% (100-second buccal exposure); absolute bioavailability plateaus due to saturable buccal absorption (Grass et al. 2021 [Ref 9]).
- **Intramuscular:** Well absorbed (~90%); rapid effective delivery for emergency use.
- **Intranasal:** Nayzilam formulation (2019) achieves effective CNS delivery; bioavailability approximately 44% reported in Phase 1 studies (Wheless 2021 [Ref 30]).

**Distribution:**
- Volume of distribution (Vd): ~1.3–2.0 L/kg in young adults (Greenblatt et al. 1984 [Ref 18])
- Vd is significantly increased in elderly men (~2.47 L/kg vs. ~1.22 L/kg in young men) and in obese patients (311 L vs. 114 L in matched controls) due to partitioning into fatty tissue (Servin et al. 1987 [Ref 34]; Greenblatt et al. 1984 [Ref 18])
- High plasma protein binding: ~96–98% (primarily albumin; Trouvin et al. 1988 [Ref 19])
- Free fraction is increased in hepatic cirrhosis: 4.9% vs. 1.9% in controls (Trouvin et al. 1988 [Ref 19])
- Rapid CNS penetration due to lipophilicity at physiological pH

**Half-life:**
- IV t½: ~2.1 hours in young males; ~5.6 hours in elderly males (Greenblatt et al. 1984 [Ref 18])
- ~4.0 hours in elderly females; ~2.6 hours in young females (no significant age effect in women [Ref 18])
- Perioperative setting: ~135 minutes in normal patients; ~168 minutes in cirrhotic patients (Trouvin et al. 1988 [Ref 19])
- Elderly males (>80 years): t½ prolonged to ~8.52 hours vs. ~2.77 hours in young males (Servin et al. 1987 [Ref 34])
- **Important:** Context-sensitive half-time lengthens with prolonged continuous infusion in ICU; duration of effect is highly dependent on duration of administration (Olkkola & Ahonen 2008 [Ref 17])

**Clearance:**
- Total plasma clearance: ~637 ml/min in normal patients (Trouvin et al. 1988 [Ref 19])
- Reduced in cirrhosis: ~402 ml/min
- Reduced in elderly males: ~4.4 ml/min/kg vs. ~7.8 ml/min/kg in young males (Greenblatt et al. 1984 [Ref 18])
- High hepatic extraction ratio; primarily flow-dependent elimination

**Metabolism:**
- Primary pathway: CYP3A4-mediated hydroxylation to 1'-hydroxymidazolam (the major and pharmacologically active metabolite) and 4-hydroxymidazolam (minor; inactive) (Kassab et al. 2026 [Ref 16]; Olkkola & Ahonen 2008 [Ref 17])
- Secondary CYP: CYP3A5 (contributes to interindividual variability); minor CYP2C19 involvement (Kassab et al. 2026 [Ref 16])
- Phase 2: Both hydroxy-metabolites undergo UDP-glucuronosyltransferase (UGT)-mediated glucuronide conjugation
- **Critical safety issue:** 1'-hydroxymidazolam-β-D-glucuronide retains pharmacological activity at the benzodiazepine receptor (Ki ~16 nmol/L vs. midazolam Ki ~1.4 nmol/L — approximately 10-fold weaker). In patients with severe renal failure, this active conjugate accumulates, causing prolonged sedation reversible by flumazenil (Bauer et al. 1995 [Ref 20]; Procak et al. 2025 [Ref 21])
- Sex, age, inflammation, and drug interactions affect midazolam disposition complexity (Procak et al. 2025 [Ref 21])

**Onset and peak:**
- IV administration: clinical sedation within 2–3 minutes; peak effect within 3–5 minutes
- Oral: onset 30–60 minutes; peak ~1–2 hours (consistent with seed data)
- IM: onset 5–15 minutes; peak ~30–60 minutes
- Intranasal: onset 3–5 minutes (rapid CNS delivery)
- Buccal: onset 5–10 minutes

---

## History

**Broader class context:** The benzodiazepine class was discovered serendipitously in 1955 by Hoffmann-La Roche chemist Leo Sternbach, leading to chlordiazepoxide (Librium, 1960) and diazepam (Valium, 1963). The association of benzodiazepines with GABA mechanisms was established approximately 15 years after their discovery (Wick 2013 [Ref 29]).

**Synthesis and discovery:** Midazolam was first synthesized in 1975 by chemists Armin Walser and Rodney Fryer at Hoffmann-La Roche, Inc. in the United States. The compound was patented by Hoffmann-La Roche in 1976. Walser and colleagues published the synthesis details in 1978. It was the first benzodiazepine specifically designed to be water-soluble through the mechanism of imidazole ring fusion, enabling stable aqueous injectable formulations [Ref 27].

**FDA approval:** Midazolam received U.S. FDA approval in 1985 under the brand name Versed (injection), marketed by Hoffmann-La Roche. It was the first benzodiazepine produced primarily for use in anaesthesia [Refs 27, 28]. Early landmark reviews established its clinical profile (Reves et al. 1985 [Ref 1]; Dundee et al. 1984 [Ref 41]; Kanto 1985 [Ref 42]).

**WHO recognition:** Midazolam has been included on the WHO Model List of Essential Medicines, recognizing its global medical importance in sedation, anesthesia, and seizure management.

**New formulation approvals:**
- **2019:** FDA approved Nayzilam (midazolam nasal spray, 5 mg per spray) for the acute treatment of seizure clusters (intermittent, stereotypic episodes) in patients ≥12 years with epilepsy (Wheless 2021 [Ref 30]; Penovich et al. 2024 [Ref 31]).
- European buccal midazolam formulations have been approved for acute convulsive seizures.

**Controversial use — lethal injection:** In the 2010s, midazolam was introduced as a component of execution protocols in several U.S. states, replacing pentobarbital after that drug's manufacturer restricted its availability for executions. The use of midazolam in executions has been highly controversial: critics argue that midazolam, as a sedative rather than a true anesthetic, may not adequately anesthetize prisoners before administration of painful execution drugs. Dr. Armin Walser, one of the co-inventors of midazolam, publicly opposed its use in executions, stating the drug was not made for that purpose. In 2015, the U.S. Supreme Court upheld the use of midazolam in executions (Glossip v. Gross) [Ref 27].

---

## Subjective Effects

**Source note:** The subjective effects of midazolam are well-characterized from decades of controlled clinical trials, pharmacodynamic studies, and observational data in surgical and procedural sedation contexts. User report databases contain additional anecdotal data but no large controlled human recreational studies exist; this section primarily reflects clinical pharmacology literature.

**Sedation and hypnosis:** Dose-dependent progression from light anxiolysis to deep sedation to general anesthesia. At standard procedural sedation doses (0.05–0.1 mg/kg IV), most patients experience comfortable drowsiness and reduced anxiety. Higher doses or rapid IV administration produce loss of consciousness (Khanderia & Pandit 1987 [Ref 2]).

**Anterograde amnesia:** One of midazolam's most clinically notable and reliable effects. Occurs at sub-sedating doses. Patients may appear awake and responsive but form no explicit memories of the period after drug administration. Dose and age are both associated with depth of amnesia (Chen et al. 2016 [Ref 55]). The amnesia is anterograde (loss of new memory formation after administration); retrograde amnesia is not clinically significant (Reves et al. 1985 [Ref 1]). This property is exploited in procedural sedation to reduce traumatic memory formation.

**Anxiolysis:** Reduction in anticipatory anxiety at low doses, independent of sedation. Patients report feeling calm and unconcerned prior to surgical procedures (Khanderia & Pandit 1987 [Ref 2]).

**Disinhibition:** Social disinhibition and mild euphoria have been reported at subanesthetic doses, particularly when administered intravenously. Users may experience increased sociability, loquaciousness, and reduced social inhibition. This contributes to its misuse potential.

**Muscle relaxation:** Centrally-mediated, dose-dependent reduction in muscle tone via spinal cord GABA-A effects.

**Anticonvulsant activity:** Midazolam suppresses both normal high-frequency oscillations and pathological epileptiform activity in amygdala and hippocampus. Inhibition is more pronounced in non-epileptogenic regions; seizure onset zones show less HFO reduction (Hebel et al. 2024 [Ref 6]).

**Paradoxical excitatory reactions:** Approximately 1–15% of patients — most commonly elderly, children, and those with psychiatric co-morbidities — experience paradoxical reactions including agitation, combativeness, restlessness, and increased anxiety rather than the expected sedation. In neonates, myoclonic-like movements have been reported and reversed by flumazenil (Zaw et al. 2001 [Ref 36]).

**Duration (from clinical data):**
- IV onset: 2–3 minutes; peak 3–5 minutes; duration of procedural sedation 15–80 minutes depending on dose
- Oral onset: 30–60 minutes; peak 1–2 hours; total duration 2–4 hours (consistent with seed data)
- Recovery of psychomotor function after intranasal midazolam spray: within 240 minutes (Wheless 2021 [Ref 30])

**Dose–response relationship:**
- 0.01–0.03 mg/kg IV: anxiolysis, light sedation
- 0.03–0.1 mg/kg IV: conscious sedation with anterograde amnesia (standard procedural dose)
- 0.1–0.2 mg/kg IV: deep sedation, may progress to loss of consciousness
- >0.2 mg/kg IV: loss of consciousness; general anesthesia (less reliable than thiopental for induction)
- Oral: 7.5–15 mg (adults); 0.25–0.5 mg/kg (children) for premedication

---

## Safety & Toxicity

### Animal Toxicity (Schlappi 1983 [Ref 54])
- **Oral LD50 (rat and mouse):** approximately 1,600 mg/kg
- **IV LD50:** 75 mg/kg (rat), 50 mg/kg (mouse)
- Subchronic (13-week) oral toxicity studies at high doses showed minimal toxicity; increased liver weight in rats and alkaline phosphatase in dogs (species-specific, not considered clinically relevant to humans)
- Not embryotoxic, not teratogenic (animal studies)
- No effect on fertility or postnatal development
- No mutagenicity in Ames test or fluctuation test

### Human Overdose
No published human LD50 data. Benzodiazepine overdose alone is rarely fatal in healthy adults with supportive care. The safety profile is dramatically worsened by co-administration of other CNS depressants:
- **Opioids:** synergistic respiratory depression — a major cause of benzodiazepine-related deaths in the opioid overdose epidemic context
- **Alcohol:** additive CNS depression
- **Other benzodiazepines:** additive
- **Tricyclic antidepressants (TCAs):** dangerous combination; flumazenil reversal is CONTRAINDICATED in TCA co-ingestion as it unmasks TCA seizures and arrhythmias (Lheureux et al. 1992 [Ref 37])

Overdose symptoms: ataxia, nystagmus, slurred speech, hypotension, excessive sedation, respiratory depression, coma.

**Antidote:** Flumazenil (IV). Duration of flumazenil action (30–60 minutes) is shorter than midazolam in most clinical scenarios, so resedation can occur within 1–2 hours; repeated dosing or continuous infusion may be required (Brogden & Goa 1991 [Ref 43]).

### Respiratory Depression
Dose-dependent ventilatory depression is clinically significant. Midazolam reduces hypoxic and hypercapnic ventilatory drive. Risk is substantially increased when combined with opioids (synergistic effect) (Olkkola & Ahonen 2008 [Ref 17]). Respiratory monitoring is mandatory during IV administration.

Notably, in treated status epilepticus patients, the rate of respiratory depression with benzodiazepines is *lower* than in untreated SE patients, indicating that respiratory compromise is an important consequence of uncontrolled seizures themselves (Glauser et al. 2016 [Ref 8]).

### Active Metabolite Accumulation (Renal Failure)
**FLAG (safety-critical):** The active glucuronide conjugate of 1'-hydroxymidazolam (1'-OH-midazolam-β-D-glucuronide, Ki ~16 nmol/L) accumulates in patients with severe renal failure and can cause unexpectedly prolonged sedation. This occurred even when parent drug and unconjugated metabolite concentrations were below therapeutic range (Bauer et al. 1995 [Ref 20]). This has major implications for ICU dosing.

### Cardiovascular Effects
Midazolam causes a modest reduction in mean arterial pressure and a slight increase in heart rate due to decreased systemic vascular resistance. Cardiovascular effects are generally mild compared to thiopental, contributing to its safety advantage in hemodynamically compromised patients (Reves et al. 1985 [Ref 1]).

### Reproductive Toxicity
Animal studies show no embryotoxicity or teratogenicity (Schlappi 1983 [Ref 54]). However, neonatal benzodiazepine exposure via maternal administration can cause neonatal sedation, hypotonia, and respiratory depression. Chronic maternal exposure can lead to neonatal withdrawal syndrome. Benzodiazepines (class D in US FDA pregnancy categories) should be used in pregnancy only when clearly necessary.

### ICU Context
In critically ill patients receiving prolonged midazolam infusions, tolerance, tachyphylaxis, accumulation, and prolonged awakening are well-recognized concerns (Roberts et al. 2012 [Ref 45]; Hasegawa et al. 2015 [Ref 13]). PADIS guidelines (Devlin et al. 2018 [Ref 7]) recommend limiting benzodiazepine use in ICU sedation due to association with delirium and prolonged mechanical ventilation.

---

## Harm Reduction

### Contraindications
- Acute narrow-angle glaucoma (benzodiazepine class contraindication)
- Hypersensitivity to benzodiazepines
- Myasthenia gravis (worsens neuromuscular blockade)
- Severe respiratory insufficiency (risk of respiratory failure)
- Sleep apnea syndrome
- Pregnancy (particularly first trimester; use only if benefit outweighs risk)
- Co-administration of potent CYP3A4 inhibitors (dose reduction required, not absolute contraindication)
- Caution: TCA co-ingestion (flumazenil reversal may be dangerous [Ref 37])

### Dose Reduction Required
- **Elderly patients:** Half-life prolonged 2–3-fold; dose should be reduced by ~30–50% [Ref 34, 18]
- **Hepatic impairment:** Cirrhosis reduces clearance by ~37%; free fraction increases [Ref 19]
- **Renal failure:** Active metabolite accumulation; monitor carefully and consider dose reduction [Ref 20]
- **Obesity:** Increased Vd extends duration; titrate carefully [Ref 18]
- **CYP3A4 inhibitors:** Dramatically increase midazolam exposure; substantial dose reduction required [Ref 33]

### Drug Interactions (Harm Reduction)
- **Opioids:** Additive/synergistic respiratory depression; lowest effective dose of each; do not administer rapidly IV together
- **Alcohol:** Additive CNS depression; avoid alcohol within hours of administration
- **CYP3A4 inhibitors** (ketoconazole, itraconazole, clarithromycin, erythromycin, ritonavir, grapefruit juice): Substantially increase midazolam plasma levels and extend duration [Ref 33]; prescribers must reduce midazolam dose
- **CYP3A4 inducers** (rifampin, carbamazepine, phenytoin): Dramatically reduce midazolam exposure (rifampin reduces oral AUC to ~24% of control) [Ref 46]; increased doses may be required

### Emergency Response
- Ensure patent airway; supplemental oxygen
- Respiratory monitoring; equipment for assisted ventilation should be immediately available
- Flumazenil 0.2 mg IV (may repeat to 1 mg maximum); onset within 1–2 minutes
- Resedation risk: flumazenil t½ is 30–60 minutes; monitor patient for 2+ hours after apparent recovery
- **Do NOT administer flumazenil** if there is any possibility of TCA co-ingestion [Ref 37]
- Supportive care: maintain ventilation, circulation
- Hemodialysis is not effective due to high protein binding

---

## Tolerance & Dependence

### Tolerance
Tolerance to most pharmacological effects of midazolam (sedation, anxiolysis, anticonvulsant, hypnotic) develops with repeated or continuous administration. Molecular mechanisms include:
1. **GABA-A receptor downregulation:** Chronic benzodiazepine exposure causes transcriptional downregulation of the α1 subunit gene via activation of L-type voltage-gated calcium channels (Foitzick et al. 2020 [Ref 49])
2. **Receptor uncoupling:** Dissociation of GABA and benzodiazepine binding sites, mediated by increased GABA-A receptor phosphorylation (γ2 subunit) (Miller 1991 [Ref 50])

In pediatric cardiac ICU patients, dose-dependent tolerance requiring escalating doses has been observed with continuous midazolam infusions (Hasegawa et al. 2015 [Ref 13]).

Subtype-selective compounds that spare α1 receptors (unlike midazolam) are in development to reduce tolerance liability (Berro et al. 2025 [Ref 12]).

### Cross-Tolerance
Full cross-tolerance exists between midazolam and other benzodiazepines (alprazolam, diazepam, lorazepam, etc.) and to some degree with other GABA-A positive modulators including alcohol, barbiturates, and Z-drugs (Miller 1991 [Ref 50]; Duke et al. 2021 [Ref 38]).

### Dependence
Physical and psychological dependence develop with regular use. Midazolam is self-administered by non-human primates (rhesus monkeys), confirming abuse liability (Berro et al. 2025 [Ref 12]).

**Extreme case report:** A 48-year-old physician developed dependence on 300 mg/day intravenous midazolam (far exceeding therapeutic doses). Withdrawal severity as measured by CIWA-B score was 68 (indicating severe withdrawal). She was treated with a gradual transition to an equivalent oral clonazepam dose over 7 days, supplemented with carbamazepine and cognitive behavioral therapy (Ramazani et al. 2024 [Ref 11]).

### Withdrawal Syndrome
Benzodiazepine withdrawal — including from midazolam — can be life-threatening at high doses of chronic use. Features include:
- Anxiety, agitation, restlessness
- Insomnia
- Tremors, muscle cramps
- Hypersensitivity to light, sound, and touch
- Seizures (potentially fatal; risk proportional to daily dose and duration of use)
- Psychosis and delirium in severe cases

**Standard withdrawal management:** Gradual taper using a long-acting benzodiazepine (typically diazepam or clonazepam) as a substitute, given the short half-life of midazolam itself.

---

## Interactions

### Pharmacokinetic Interactions (CYP3A4)

**Inhibitors (increase midazolam exposure):**
- Azole antifungals: ketoconazole, itraconazole, voriconazole — substantial increases (2–10-fold); voriconazole alone dramatically prolongs midazolam sedation (Saari et al. 2006 [Ref 32])
- Macrolide antibiotics: erythromycin, clarithromycin
- HIV protease inhibitors: ritonavir (initially inhibits, then induces with chronic use)
- Calcium channel blockers: diltiazem, verapamil (moderate)
- Nefazodone, grapefruit juice
- Clinical consequence: excessive sedation, prolonged duration, respiratory depression risk (Dresser et al. 2000 [Ref 33])

**Inducers (decrease midazolam exposure):**
- Rifampin: reduces oral midazolam AUC to ~24% of control; IV AUC to ~59% (Kharasch et al. 2011 [Ref 46])
- Carbamazepine, phenytoin, St. John's Wort: similarly reduce midazolam levels
- Clinical consequence: therapeutic failure

### Pharmacodynamic Interactions (CNS Depression)

**Opioids:** Synergistic respiratory depression; small studies suggest combined use dramatically increases risk of hypoxia, respiratory arrest, and death. This combination is a major driver of benzodiazepine-related overdose deaths.

**Alcohol:** CNS and respiratory depression; additive effects. Residual interaction at 4 hours post-IV midazolam-fentanyl is not clinically significant (Lichtor et al. 1991 [Ref 53]), but concurrent use at peak effect is dangerous.

**Other CNS depressants:** Barbiturates, other benzodiazepines, Z-drugs (zopiclone, zolpidem), antihistamines, antipsychotics — all additive CNS depression.

**Tricyclic antidepressants (TCAs):** Midazolam protects against TCA-induced seizures. However, flumazenil reversal in a patient with TCA co-ingestion unmasks TCA seizure potential and can precipitate fatal arrhythmias — a critical harm reduction consideration (Lheureux et al. 1992 [Ref 37]).

**Herb-drug interactions:** Multiple herbal products tested as CYP3A4 modulators using midazolam as a probe substrate. St. John's Wort induces CYP3A4 and reduces midazolam levels. Curcumin/piperine (PMID 22725836) has been assessed [Ref 33 class].

---

## Legal Status

| Jurisdiction | Classification |
|---|---|
| United States | DEA Schedule IV (Controlled Substances Act); DEA Number 2884 |
| United Kingdom | Schedule 3 / Class C controlled drug |
| Australia | Schedule 8 (Controlled Drug of Addiction) |
| Canada | Controlled Drugs and Substances Act (federal controlled substance) |
| European Union | Prescription-only medicine; regulated nationally; generally classified similarly to other benzodiazepines |
| International | WHO Model List of Essential Medicines |

**Key regulatory note:** Midazolam's Schedule IV classification in the US reflects the standard benzodiazepine placement as substances with medical use and limited but real abuse potential. Despite this relatively permissive legal classification, midazolam requires a prescription and has important clinical risks (dependence, respiratory depression) that warrant controlled status.

---

## Clinical Trials

**Active and completed trials found (selected relevant examples):**

| NCT ID | Title | Phase | Status | Condition | Sponsor |
|---|---|---|---|---|---|
| NCT01316445 | Pharmacodynamics of Nasal and Buccal Midazolam Using EEG | Phase 1 | Terminated | Epilepsy | Columbia University |
| NCT01390220 | Safety and Efficacy of USL261 (Intranasal Midazolam) in Seizure Clusters | Phase 3 | Terminated | Epilepsy | UCB Biopharma |
| NCT01641653 | Preop Midazolam and Blood Glucose in Non-Diabetic Perioperative Period | Phase 4 | Completed | Hernia | University of Medicine & Dentistry NJ |
| NCT03133780 | Sedation During Spinal Anesthesia (midazolam component) | Phase 2 | Completed | Sedation | Assiut University |
| NCT39230940 | DREAMS Trial: Dexmedetomidine vs Midazolam for End-of-Life Sedation | RCT | Recruiting | Palliative/agitation | (Australia) |

**Note on Nayzilam Phase III:** The pivotal Phase III trial supporting Nayzilam (midazolam nasal spray) FDA approval was conducted but NCT identifiers for the active completed pivotal studies were not found in the ClinicalTrials search; some registration occurred under earlier numbers. Published evidence from Phase I and Phase III trials is reviewed in Wheless 2021 [Ref 30].

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. Standard investigation proceeded under standing research directives.

---

## Gaps & Flags

### 🚩 CRITICAL FLAG — Characterization Error
The brief lists midazolam's characterization as **"emerging."** This is demonstrably incorrect. Midazolam:
- Was first synthesized in 1975
- Received FDA approval in 1985 (40 years ago)
- Is on the WHO Model List of Essential Medicines
- Is one of the most widely used sedative/anesthetic agents worldwide
- Has thousands of published clinical trials and studies

**Editorial action required:** Update characterization from "emerging" to something like "established" or "prescription."

### Missing Chemical Data
The brief lacks SMILES string, InChIKey, and PubChem CID. These have been confirmed:
- PubChem CID: 4192
- InChIKey: DDLIGBOFAVUZHB-UHFFFAOYSA-N
- CAS: 59467-70-8
SMILES is available from PubChem CID 4192.

### Toxicity Data in Brief — Partially Resolved
Brief notes: "Inferred from pharmacological class — not sourced from literature." This has now been partially resolved:
- Animal LD50 (Schlappi 1983 [Ref 54]): oral ~1,600 mg/kg; IV 75/50 mg/kg (rat/mouse)
- No embryotoxicity, no teratogenicity, no mutagenicity confirmed in animal studies
- **Still unresolved:** No published human LD50 data exists; fatal solo benzodiazepine overdose is rare; human acute toxicity is markedly increased by co-administration of CNS depressants

### GABA-A Subunit Binding Ki Data
Specific benzodiazepine site binding affinity (Ki) values for midazolam at individual GABA-A receptor subtype configurations were not found in the literature search. The receptor pharmacology is well-understood mechanistically, but precise subtype Ki values require further investigation or consultation with pharmacological databases (ChEMBL, BindingDB).

### Dose Sensitivity Field (Brief)
The brief lists the "dose sensitivity" field as empty. The seed dose data (Threshold 1 mg oral, etc.) appears reasonable based on clinical literature. These values are consistent with published premedication and procedural sedation dosing. **Editorial note:** The dose ranges should be reviewed by someone with clinical prescribing experience — the "heavy" IV dose listed as "5+ mg" seems low for ICU continuous sedation contexts (where mg/hr infusions are standard), though it may be correct for bolus dosing.

### Duration Data — Intravenous Offset
The seed duration data for IV shows "offset: 0.5–1.5 hours" and "total: 2–6 hours." The actual offset of clinical sedation after bolus IV midazolam is typically 15–80 minutes for a single procedural dose, which is consistent. However, after prolonged infusion (ICU context), offset can be dramatically extended due to context-sensitive half-time — the seed data does not capture this infusion context, which should be flagged as a limitation.

### Pregnancy and Lactation
Published safety data for midazolam in pregnancy is limited to animal studies (no teratogenicity) and clinical case data. No controlled human studies. Neonatal effects (sedation, hypotonia, respiratory depression) from maternal administration near delivery are well-documented. Breast milk transfer is possible but data on quantity is limited.

### No Published Recreational Use Studies
No controlled human recreational pharmacology studies of midazolam exist (as expected for a Schedule IV controlled substance). Subjective effect descriptions in harm reduction contexts are derived from clinical sedation studies, case reports of misuse, and anecdotal user reports. The abuse/recreational use literature is sparse.

### Stereochemistry — Clinical Relevance Unestablished
The rapid interconversion of midazolam enantiomers at physiological conditions means clinical use of enantiopure formulations is not feasible, and no differential pharmacology between enantiomers has been established in humans.